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Blood coagulation is the process where a cascade of enzymatic reactions generates a clot to 
stem the flow of blood following injury. Unfortunately, the same cascade can also form 
pathologic intravenous clots in a process termed venous thrombosis. Current anticoagulant 
therapies used to prevent thrombosis also carry a risk of bleeding. Further investigation of the 
basic biochemical and regulatory mechanisms underlying coagulation are required to identify 
new antithrombotic strategies with reduced risk of bleeding. The studies presented in this 
dissertation examine the interactions between three key players in the terminal stages of blood 
coagulation: factor XIII (FXIII), fibrin(ogen), and red blood cells (RBCs). 
First, we examined the mechanism of FXIII-mediated RBC retention in clots. We found that 
FXIII does not promote RBC retention by crosslinking RBCs directly to the clot or by 
modulating fibrin network density. Instead, specific FXIII-mediated crosslinking of the fibrin α-
chains is required for normal RBC retention in clots. This finding is the first to reveal a 
pathophysiologic role of α-chain crosslinking, and establishes this process as a crucial mediator 
of venous thrombosis. 
Second, we investigated the nature of the FXIII-fibrinogen binding interaction to determine 
the domains of each protein involved in binding. We found that FXIII binds to fibrinogen γ-chain 
residues 390-396 via the FXIII-B subunits. These findings enhance our understanding of this 
important interaction in both physiologic and pathologic coagulation. 
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Third, we examined the regulation of the FXIII-A and -B subunits. We found that the FXIII 
subunits exhibit inter-tissue, reciprocal regulation whereby FXIII-B promotes FXIII-A stability 
in circulation, while FXIII-A increases FXIII-B stability and production. FXIII-A upregulates 
liver RNA-binding proteins and may modulate post-transcriptional regulation of FXIII-B 
synthesis. These data clarify the mechanisms governing FXIII levels in plasma and identify a 
unique regulatory relationship between two protein subunits synthesized in different tissues. 
These data also expose a new liver-regulatory function of FXIII-A. 
Collectively, these studies greatly extend our understanding of the interactions between 
FXIII, fibrin(ogen), and RBCs, three crucial mediators of clot dynamics. Importantly, this 
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CHAPTER 1: INTRODUCTION 
 
1.1 Coagulation and venous thrombosis. 
	  
Blood coagulation is a series of enzymatic reactions that converts liquid blood into a gel-like 
clot. This process is initiated via either the intrinsic or extrinsic pathway. The resulting 
enzymatic cascades merge in a common pathway that leads to the generation of thrombin. 
Thrombin is a serine protease that cleaves soluble fibrinogen to form fibrin monomers. Fibrin 
monomers polymerize into insoluble fibers that serve as the clot structural scaffold. This scaffold 
is then strengthened by the crosslinking activity of the transglutaminase factor XIII (FXIII). 
Fibrin formation and platelet activation are crucial for hemostasis (Figure 1.1). Activated 
platelets will pull on fibrin fibers causing the clot to contract, aiding wound closure and 
minimizing blood loss following trauma. 
Unfortunately, dysregulation of normal coagulation mechanisms can cause pathologic clot 
formation, termed thrombosis (Figure 1.1). Thrombosis can occur in the arterial or venous 
circulation, leading to myocardial infarction, stroke, deep vein thrombosis, and pulmonary 
embolism. Arterial thrombosis is typically associated with atherosclerotic plaque rupture that 
exposes subendothelial cells and procoagulant material (e.g., tissue factor, collagen) to blood, 
leading to platelet activation and aggregation in high shear. Ultimately, platelet accumulation and 
fibrin deposition produce an occlusive platelet-rich “white thrombus” (reviewed in 4). In contrast, 
venous thrombosis/thromboembolism is thought to be triggered by inappropriate expression of 




Figure 1.1. Hemostasis and venous thrombosis. Coagulation is initiated via either the intrinsic 
or extrinsic pathway. The two pathways meet at the common pathway that ultimately converts 
prothrombin (II) to thrombin (IIa). Thrombin then converts soluble fibrinogen into insoluble 
fibrin that polymerizes to form the structural scaffold of the clot. Coagulation factor XIII (FXIII) 
introduces covalent crosslinks in the fibrin network. Crosslinked fibrin, along with platelets and 
red blood cells (RBCs) comprise a clot. Unfortunately, the same mechanisms that generate a 
physiologic, hemostatic clot can also lead to pathologic venous thrombosis. Consequently, 
current anticoagulants target processes upstream of fibrin formation to prevent thrombosis. This 
dissertation examines the basic mechanisms underlying the terminal steps of coagulation. 
Chapter 2 investigates how FXIII promotes RBC retention in clots. Chapter 3 examines the 
FXIII-fibrin(ogen) binding interaction. Chapter 4 examines the regulation of FXIII subunits.  
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shear (reduced blood flow [stasis]). Venous thrombi are large clots primarily composed of fibrin 
and red blood cells (RBCs). Consequently, venous thrombi are known as “red thrombi.”  
Both arterial and venous thrombosis are significant public health concerns. Specifically, 
venous thrombosis affects over 1 in 1000 Americans annually, with each occurrence costing an 
average of $33,000 in the year following initial diagnosis.5,6 30% of venous thrombosis patients 
will die within 30 days of diagnosis, mostly due to pulmonary embolism. Up to one-half of 
surviving patients will develop recurrent venous thrombosis or suffer from post-thrombotic 
syndrome, which is characterized by pain, edema, and leg ulcers.6-8 
Current anticoagulant therapies target clotting factors upstream of fibrin formation (e.g. 
warfarin, heparin, dabigatran, rivaroxaban, Figure 1.1). These therapies are all associated with a 
risk of bleeding, and further investigation of the basic biochemical mechanisms underlying 
coagulation is required to reveal novel antithrombotic strategies associated with minimal risk of 
bleeding.8 One region of the coagulation cascade that may contain promising antithrombotic 
targets is the FXIII-fibrin(ogen) axis. Targeting processes after fibrin formation that mediate 
thrombus size and stability might reduce venous thrombosis, but persevere the body’s ability to 
form a fibrin clot, reducing the risk of associated bleeding. However, the precise nature of 
interactions between FXIII, fibrin(ogen), and another key venous thrombus component, RBCs, 
are still unclear. This dissertation will probe the FXIII-fibrin(ogen)-RBC axis and provide insight 
into basic biochemical mechanisms governing these important players in hemostasis and 
thrombosis. 
1.2 Fibrin(ogen) and factor XIII.  
	  
Fibrinogen is a 340-kDa glycoprotein that circulates in plasma at a high concentration (2-4 
mg/mL).9 Fibrinogen consists of two sets of three chains (AαBβγ)2 arranged in a trinodular 
 4 
structure. The N-termini of these chains are located in a central E-domain with the C-termini of 
the Bβ- and γ-chains making two distal D-domains. The C-termini of the longer Aα-chains (αC) 
are largely disordered and thought to loop back and interact with the E-domain.10-12 Following 
the activation of coagulation and thrombin generation, thrombin cleaves fibrinopeptides A and B 
from the N-termini of the Aα- and Bβ-chains, respectively, yielding a fibrin monomer. Fibrin 
monomers then polymerize in a half-staggered orientation to form protofibrils. Protofibrils then 
laterally aggregate to form the fibrin fibers that make up the insoluble fibrin network, which 
serves as the structural scaffold of the clot (Figure 1.2).10  
FXIII is one of 9 members of a superfamily found in both cellular (transglutaminases 1-7 and 
erythrocyte band 4.2) and plasma (plasma FXIII) compartments. The cellular forms of FXIII are 
present in multiple cell types, including monocytes, megakaryocytes, osteoblasts, and platelets 
(reviewed in 13). Plasma FXIII is unique because it circulates as two catalytic subunits (FXIII-
A2) and two non-catalytic subunits (FXIII-B2) arranged in a non-covalent heterotetramer (FXIII-
A2B2, Mr 325 kDa, ~70 nM, 14-28 µg/mL).14 Mechanisms mediating the interactions between 
the A and B subunits are reviewed by Schroeder and Kohler15. Essentially all FXIII-A2B2 
zymogen circulates in complex with fibrinogen.16 Although older studies implicated the 
alternatively-spliced fibrinogen γ-chain (termed γ') in FXIII-A2B2 binding17,18, a more recent 
study using recombinant fibrinogen suggested FXIII-A2B2 binds both γA- and γ'-containing 
molecules with similar affinity (KD ~40 nM)19. This finding suggests other regions of fibrinogen 
mediate the interaction between FXIII-A2B2 and fibrinogen. Both older20 and more recent21 
studies identified regions in the fibrinogen α-chain that bind FXIII. Smith et al.21 found that 
FXIII-A2B2 binds a peptide containing amino acid residues 371-425 of the fibrinogen αC domain 
with high affinity (KD 5-30 nM). However, they did not demonstrate binding of FXIII-A2B2 to 
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Figure 1.2. FXIIIa crosslinking during fibrin formation. Fibrinogen is a hexamer composed 
of 2 Aα- (purple), 2 Bβ- (blue), and 2 γ-chains (green). During coagulation, thrombin cleaves N-
terminal fibrinopeptides from the Aα- and Bβ-chains, producing fibrin monomers which 
polymerize into protofibrils and subsequently, fibers.10 FXIIIa increases clot stability by 
introducing ε-N-(γ-glutamyl)-lysyl crosslinks between residues in the γ- and α-chains of fibrin 
monomers within individual fibers. FXIIIa first introduces crosslinks between γ-chains (forming 
γ-γ dimers) and subsequently between γ- and α-chains (forming high molecular weight species 
[γ-multimers, α-polymers, and αγ-hybrids]).3,22-24 Figure originally appeared in Byrnes and 
Wolberg.25 Adapted from and reprinted with permission from Thieme Medical Publishers, the 
publisher of Seminars in Thrombosis and Hemostasis. 
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this region on full-length fibrinogen and suggested that the interaction between FXIII-A2B2 and 
the αC region may arise during FXIII activation, and that other fibrinogen residues bind 
zymogen FXIII-A2B2 in circulation.21 We showed that murine fibrin(ogen) containing alanine 
mutations within γ-chain residues γ390-396 (Fibγ390-396A) exhibits decreased binding of FXIII-
A2B2, suggesting these residues mediate the carrier function in mice.26  
During activation of plasma FXIII-A2B2, thrombin first catalyzes the cleavage of activation 
peptide(s) from the N-termini of the FXIII-A subunits (FXIII-A2'B2).27,28 Calcium then promotes 
dissociation of the FXIII-B subunits from FXIII-A2', yielding activated FXIII-A2* (FXIIIa).29 
FXIIIa catalyzes the formation of intermolecular ε-N-(γ-glutamyl)-lysyl isopeptide bonds 
between glutamine residues 398/399 and lysine 406 in the fibrin γ-chain and subsequently 
between glutamine and lysine residues in the α-chain (Figure 1.2). Plasma FXIII activation is 
accelerated when it is bound to fibrinogen, which facilitates dissociation of the FXIII-B 
subunits.20,30,31 This function ascribes fibrin(ogen) with an important regulatory role during 
FXIII(a) activation and activity. Plasma from mice that have reduced binding of FXIII-A2B2 to 
fibrin(ogen) (Fibγ390-396A mice) exhibits delayed activation of FXIII-A2B2 and slower formation 
of fibrin γ- and α-chain crosslinks.26 
Crosslinking profoundly affects the viscoelastic properties of the fibrin network.22,32-35 
FXIIIa-mediated crosslinking significantly increases the elastic modulus (stiffness) of both 
individual fibrin fibers33,34,36 and whole clot networks32, and is required to protect the clot against 
premature disruption or dissolution (Figure 1.3). Using a synthetic FXIII inhibitor and a patient-
derived antibody to selectively inhibit the formation of high molecular weight (HMW) 
crosslinked species yet permit γ-γ dimer formation, Ryan et al.22 showed that γ-chain 







Figure 1.3. Contributions of FXIIIa to clot biochemical and mechanical stability. FXIIIa 
crosslinking of plasma proteins [i.e. α2-antiplasmin, (α2-AP)] increases the resistance of the clot 
to fibrinolysis. Crosslinking of the fibrin α- (purple) and γ-chains (green) increases the 
mechanical stability of the clot. Increased mechanical stability stiffens and renders the clot more 
resistant to shear forces. Adapted from a figure that originally appeared in Byrnes and 
Wolberg.25 Reprinted with permission from Thieme Medical Publishers, the publisher of 
Seminars in Thrombosis and Hemostasis.  
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correlated with the formation of α-chain-rich, HMW crosslinked species.22 More recent studies 
using a recombinant fibrinogen mutated to eliminate γ-chain crosslinking sites confirmed that α-
chain crosslinking is the primary contributor to clot stiffness and elasticity.3,23,24 Interestingly, 
however, fibrin crosslinking has little effect on gross fibrin network morphology, producing, at 
most, only a minor (~12%) increase in fibrin network density.3,37-40 
FXIII(a) also has critical anti-fibrinolytic functions during coagulation, mediated via its 
ability to crosslink antifibrinolytic proteins, including α2-antiplasmin41,42, thrombin activatable 
fibrinolysis inhibitor43, and type-2 plasminogen activator inhibitor44 to fibrin (Figure 1.3). This 
activity is mediated primarily by plasma FXIII-A2*. However, in situations in which the 
concentration of plasma FXIII is low (≤10%), platelet FXIII-A2* exposed on the platelet surface 
also promotes fibrin stability by crosslinking α2-antiplasmin to fibrin.45,46 
1.3 FXIII-fibrin(ogen) axis and clot RBC content. 
	  
 Previous work in our laboratory showed that FXIIIa activity is also a major determinant of 
thrombus RBC content.26 Briefly, in in vitro clot contraction assays where whole blood is clotted 
and platelet-mediated clot contraction is allowed to occur, we observed reduced RBC retention 
and clot size in clots formed in the presence of a FXIIIa inhibitor or from both mouse and human 
FXIII-deficient plasma.26 Similar to the in vitro assays, FXIII-deficient mice subjected to in vivo 
venous thrombosis models produced smaller thrombi with reduced RBC content relative to 
controls.26 These data are consistent with the “excessive red cell fallout” previously reported in a 
family with congenital FXIII deficiency47, and demonstrate a newly-recognized function for 
FXIII(a) during clot formation (Figure 1.4). This finding also suggests that FXIIIa could be a 
therapeutic target for the reduction of venous thrombosis.  However, how FXIIIa promotes RBC 

































Figure 1.4. FXIIIa mediates RBC retention in clots. Under normal circumstances, FXIII is 
activated during clotting and promotes the inclusion of RBCs in the clot. When FXIIIa activity is 
deficient or delayed, RBC retention in the clot is significantly diminished, reducing clot size. 
Chapter 2 examines how FXIIIa promotes clot RBC retention. Chapter 3 characterizes the FXIII-
fibrinogen interaction that is crucial for normal RBC retention. Figure originally appeared in 
Walton et al.48 Reprinted with permission from John Wiley and Sons, the publisher of the 
Journal of Thrombosis and Haemostasis. 
  
 10 
mechanism of FXIIIa-mediated RBC retention. Briefly, we show that FXIIIa does not directly 
crosslink RBCs into the clot. Instead, FXIIIa-mediated crosslinking of fibrin α-chains promotes 
RBC retention in forming clots.40 
 Prior work in our laboratory also showed that blood from Fibγ390-396A mice subjected to our in 
vitro clot contraction assay produces ~5-fold smaller clots with ~3.5-fold reduced RBC retention 
compared to clots formed from wild-type blood. Fibγ390-396A mice also exhibit reduced thrombus 
size and reduced RBC retention in in vivo venous thrombosis models.26 Given that these mice 
exhibit impaired FXIII-fibrinogen binding and delayed FXIII activation26, these results suggest 
that not only is FXIIIa activity important for RBC retention in clots, but the timing of FXIII 
activation, and therefore FXIII-fibrinogen interactions, are also crucial determinants of RBC 
retention in clots (Figure 1.4). This finding suggests that FXIII-fibrinogen binding, and not just 
FXIIIa activity, could be therapeutically targeted to reduce venous thrombosis. However, the 
nature of the FXIII-fibrinogen binding interaction was still unknown. In a study presented in 
Chapter 3, we investigate the critical regions of FXIII and fibrinogen involved in this binding 
interaction. Briefly, we determine that FXIII binds to fibrinogen γ-chain residues 390-396 via the 
FXIII-B subunits.49 
1.4 FXIII subunit regulation. 
	  
 The FXIII-A and -B subunits arise from different tissues. Transplantation studies show 
FXIII-A polymorphisms track with bone marrow transplantation in humans, suggesting cells of 
bone marrow origin produce plasma FXIII-A.50 Consistent with this premise, recent murine 
Cre/lox studies implicate tissue resident macrophages in plasma FXIII-A production.51 FXIII-B 
polymorphisms track with liver transplantation in humans50, and hepatoma cell lines synthesize 
FXIII-B in vitro52, suggesting that the liver synthesizes FXIII-B. However, both the mouse liver 
 11 
and kidney contain F13b mRNA.53 Once secreted, the FXIII subunits assemble in plasma to form 
FXIII-A2B2. Relative to FXIII-A, there is a two-fold molar excess of FXIII-B. Consequently, 
essentially all plasma FXIII-A circulates tightly bound to FXIII-B (KD~10-10) and there is a pool 
of uncomplexed FXIII-B (43-62 nM).54  
It is well-established that the FXIII-B subunits stabilize the FXIII-A subunits.53,55,56 In the 
absence of FXIII-B, FXIII-A has a half-life of <10 hours55, whereas the FXIII-A2B2 complex 
circulates for 9-10 days.57 Consequently, FXIII-B deficiency results in FXIII-A deficiency. 
Intriguingly, we49 and others53 have shown FXIII-A-deficient mice have significantly decreased 
plasma FXIII-B. Similar trends are observed in humans, with FXIII-A-deficient individuals 
exhibiting less than 50% normal FXIII-B.58  Furthermore, recombinant FXIII-A2 infusion in both 
monkeys59 and humans55 increases plasma FXIII-B. FXIII-B continues to rise even after FXIII-
A2B2 begins to fall. Collectively, these data suggest FXIII-A and FXIII-B exhibit a unique, inter-
tissue reciprocal regulation, whereby FXIII-B stabilizes FXIII-A and FXIII-A mediates FXIII-B 
levels. 
The mechanism driving this reciprocal regulation is unclear. In an ongoing study presented in 
Chapter 4, we use in vivo mouse models, in vitro cell culture, and proteomic profiling to 
examine how FXIII-A regulates FXIII-B. Briefly, we show that FXIII-A both reduces FXIII-B 
clearance from plasma and induces de novo FXIII-B production in the liver (Figure 1.5). FXIII-
A causes differential regulation of RNA-binding proteins in the liver, but not in the kidney, 





Figure 1.5. Inter-tissue, reciprocal FXIII subunit regulation. Studies presented in Chapter 4 
examine the mechanisms underlying the inter-tissue, reciprocal regulation of FXIII subunits. 
Briefly, FXIII-A subunits are synthesized in cells of bone-marrow origin and secreted into the 
plasma. FXIII-A then induces de novo hepatic FXIII-B production. In plasma, FXIII-A and -B 
subunits assemble into the FXIII-A2B2 complex, which stabilizes both subunits. FXIII-A2B2 then 
circulates bound to fibrinogen. 
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1.5 Focus of this dissertation. 
	  
Although current anticoagulants are effective at preventing thrombosis, they also carry a risk 
of bleeding. Continued study of the biochemical mechanisms underlying clotting is necessary to 
identify therapeutic targets that will prevent pathologic thrombosis yet preserve physiologic 
hemostasis. The focus of this dissertation is to expand our understanding of FXIII and fibrinogen 
function and the regulatory processes affecting these important coagulation proteins. This 
dissertation blends basic biochemical approaches with in vitro and in vivo models to determine: 
1) how FXIII activity mediates RBC retention in clots, 2) how FXIII and fibrin(ogen) interact, 
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CHAPTER 2: FACTOR XIIIa-DEPENDENT RETENTION OF RED BLOOD CELLS IN 




 Factor XIII(a) [FXIII(a)] stabilizes clots and increases resistance to fibrinolysis and 
mechanical disruption. FXIIIa also mediates red blood cell (RBC) retention in contracting clots 
and determines venous thrombus size, suggesting FXIII(a) is a potential target for reducing 
venous thrombosis. However, the mechanism by which FXIIIa retains RBCs in clots is unknown. 
We determined the effect of FXIII(a) on human and murine clot weight and composition. Real-
time microscopy revealed extensive RBC loss from clots formed in the absence of FXIIIa 
activity, and RBCs exhibited transient deformation as they exited the clots. Fibrin band-shift 
assays and flow cytometry did not reveal crosslinking of fibrin or FXIIIa substrates to RBCs, 
suggesting FXIIIa does not crosslink RBCs directly to the clot. RBCs were retained in clots from 
mice deficient in α2-antiplasmin, thrombin-activatable fibrinolysis inhibitor, or fibronectin, 
indicating RBC retention does not depend on these FXIIIa substrates. In the presence of FXIIIa, 
RBC retention in clots was positively correlated with final network density; however, FXIIIa 
inhibition abrogated this correlation. FXIIIa inhibition reduced RBC retention in clots formed 
with fibrinogen that lacks γ-chain crosslinking sites, but not in clots that lack α-chain 
crosslinking sites. Moreover, FXIIIa inhibitor concentrations that primarily block α-, but not γ-, 
chain crosslinking decreased RBC retention in clots. These data indicate RBC retention in clots 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 This chapter previously appeared as an article in Blood. The original citation is as follows: Byrnes JR, Duval C, 
Wang Y, Hansen CE, Ahn B, Mooberry MJ, Clark MA, Johnsen JM, Lord ST, Lam W, Meijers JCM, Ni H, Ariëns 
RAS, Wolberg AS. Factor XIIIa-dependent red blood cell retention in clots is mediated by fibrin α-chain 
crosslinking. Blood. 2015;126(16):1940-1948. 
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is mediated by fibrin α-chain crosslinking. These findings expose a newly-recognized, essential 
role for fibrin crosslinking during whole blood clot formation and consolidation, and establish 
FXIIIa activity as a key determinant of venous thrombus composition and size. 
2.2 Introduction 
	  
 Fibrinogen is a 340 kD plasma glycoprotein comprised of two sets each of three chains (Aα, 
Bβ, and γ) that circulates at 2-4 mg/mL. During coagulation, thrombin cleaves N-terminal 
peptides from the Aα- and Bβ-chains, producing fibrin monomers which polymerize into 
protofibrils and subsequently, fibers.1 Fibrinogen deficiency is associated with bleeding and/or 
thrombosis2, whereas elevated fibrinogen (hyperfibrinogenemia) is associated with thrombosis3-5. 
 Factor XIII (FXIII) is a plasma protransglutaminase comprised of two A (FXIII-A) and two 
B (FXIII-B) subunits that circulate as a heterotetrameric zymogen (FXIII-A2B2). FXIII activation 
occurs via thrombin-mediated cleavage of an N-terminal activation peptide from FXIII-A, and 
calcium-mediated dissociation of the inhibitory, carrier FXIII-B subunits, rendering catalytically-
active FXIIIa.6 FXIII deficiency is associated with frequent bruising, hematomas, miscarriage, 
poor wound healing, and intracranial hemorrhage.7 
 FXIIIa increases clot stability by introducing ε-N-(γ-glutamyl)-lysyl crosslinks between 
residues in the γ- and α-chains of fibrin monomers within individual fibers. Although 
crosslinking causes only subtle-to-no changes in fibrin network morphology8,9, crosslinking 
significantly decreases the extensibility and elasticity of individual fibers, and increases fibrin 
elastic modulus (stiffness)10-14. Interestingly, these effects are specifically associated with 
formation of high molecular weight (HMW) crosslinked fibrin species (γ-multimers, α-polymers, 
and αγ-hybrids).14-17 Studies using recombinant fibrinogen that cannot undergo γ-chain 
crosslinking (γQ398N/Q399N/K406R [γNNR]) reveal that fiber stiffening is primarily due to α-
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chain crosslinking.15-17 Crosslinking of other plasma proteins (e.g., α2-antiplasmin, fibronectin) 
to fibrin increases the resistance of the network to biochemical degradation (reviewed in 6). 
Together, these studies demonstrate the multifunctional role of FXIIIa in clot mechanical and 
biochemical properties. 
 Recently, we showed that FXIIIa also mediates clot composition and size during whole blood 
clot formation.18 Using an in vitro clot contraction (also called retraction) assay, we found that 
human and mouse whole blood clots formed in the absence of plasma FXIII or presence of a 
FXIIIa inhibitor have reduced retention of red blood cells (RBCs) and are significantly smaller 
than normal clots. Importantly, compared to wild-type controls, FXIII-deficient mice produce 
smaller venous thrombi that contain significantly fewer RBCs, suggesting FXIIIa-mediated 
retention of RBCs in clots modulates thrombus size.18 Collectively, these results reveal a 
previously unrecognized function for FXIIIa activity during venous thrombosis (VT) and suggest 
FXIIIa is a potential therapeutic target for reducing VT. However, the mechanism by which 
FXIIIa mediates RBC retention in clots is not known. 
 Herein, we show that FXIIIa mediates RBC retention in clots specifically via its ability to 
crosslink fibrin α-chains. These results define new (patho)physiologic roles for FXIIIa activity 
and fibrin α-chain crosslinking in hemostasis and thrombosis. 
2.3 Methods 
	  
 Proteins and Materials. Tissue factor (TF, Innovin®) was from Siemens. T101 was from 
Zedira. A15 peptide was from Kerafast. Biotinylated cadaverine and Alexa Fluor® 488 
streptavidin were from Life Technologies. 6X Laemmli sample buffer containing sodium 
dodecyl sulfate was from Boston Bioproducts. Tris-glycine gels (10%) were from Bio-Rad. 
Human α-thrombin, plasma FXIII-A2B2, and Peak 1 human fibrinogen were from Enzyme 
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Research Laboratories. Anti-human fibrinogen antibody was from Dako and Alexa Fluor® 488 
anti-rabbit secondary was from Jackson Immunoresearch. PE-labeled anti-human CD235a was 
from Biolegend. Dulbecco’s modified Eagle’s medium/Ham’s F12, 50/50 mix was from 
Corning. Octadecyl rhodamine B chloride was from Invitrogen and Alexa Fluor® 488 and 647 
dyes were from Molecular Probes. ε-aminocaproic acid (ε-ACA) was from Sigma. Normal 
human pooled plasma was prepared from 34 healthy male and female donors as previously 
described.19 Phlebotomy was approved by the University of North Carolina and Georgia Institute 
of Technology Institutional Review Boards and performed on consenting donors in accordance 
with the Declaration of Helsinki. Murine studies were approved by the University of Amsterdam 
Academic Medical Center Animal Care and Use Committee and St. Michael's Hospital Animal 
Care Committee. 
 
 Human blood clot contraction. Clot contraction assays were performed as described.18 
Briefly, blood was drawn from healthy donors via venipuncture and added to siliconized wells of 
a 96-well plate containing TF (1 pM, final), CaCl2 (10 mM, final), and the FXIIIa active site 
inhibitor, T101 (10 µM, final) or HEPES-buffered saline (20 mM HEPES, 150 mM NaCl, pH 7.4 
[HBS]). Clot formation and contraction were allowed to proceed for 90 minutes at 37°C. Serum 
RBC content was measured by absorbance (575 nm) with a SpectraMax Plus 340 plate reader 
(Molecular Devices) and compared with the initial absorbance. Clots were weighed and/or 
prepared for microscopy. 
 For experiments using recombinant fibrinogen, blood was drawn from a fibrinogen-deficient 
individual (<40 mg/dL fibrinogen, infinite thrombin clotting time, Supplemental Figure 2.1) and 
processed to platelet-rich plasma (PRP) by centrifugation (150xg, 20 minutes). PRP was then 
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processed to platelet-poor plasma (PPP) by centrifugation (1500xg, 10 minutes). PPP was flash-
frozen in liquid nitrogen and stored at -80°C. Platelets and RBCs were isolated from healthy, 
consenting, blood-type O-negative donors as described18, and counted on a pocH-100i 
Hematology Analyzer (Sysmex). Platelets (200,000/µL, final) and RBCs (2 million/µL, final) 
were then added to thawed fibrinogen-deficient plasma and supplemented with recombinant 
fibrinogen (0.25 mg/mL, final in plasma fraction, unless otherwise noted) before clot contraction 
was initiated with TF (1 pM, final) and recalcification (10 mM, final).  
 
 Microscopy. For real-time confocal microscopy of contracting clots, RBCs were isolated 
from whole blood and fluorescently-labeled with octadecyl rhodamine B chloride. Alexa Fluor® 
488-labeled fibrinogen (75 µg/mL, final) and labeled RBCs (10%, final) were added to whole 
blood and clotting was triggered with TF (1 pM, final) and recalcification (10 mM, final) in 
siliconized glass-bottom petri dishes at 37°C and 60% humidity. Reactions were performed in 
the presence of the fibrinolysis inhibitor ε-ACA (5 mM, final), in the absence and presence of 
T101. 
 For real-time difference interference contrast microscopy, clot contraction in whole blood 
was triggered in a polydimethylsiloxane microfluidics device with thrombin (1 U/ml [10 nM], 
final), CaCl2 (10 mM, final), and T101 (500 µM, final).  
 For laser scanning confocal microscopy, normal pooled plasma clots were generated in 
LabTek chambered coverglass (Nalge Nunc) by recalcification in the presence of phospholipids 
(4 µM, final), TF (1, 10, or 100 pM, final) and Alexa Fluor 647-labeled fibrinogen (10 µg/150 µL 
sample) as described.20 After 2 hours, the fibrin network was imaged using a Zeiss LSM710 laser 
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scanning confocal microscope with a 63X oil-immersion lens (Carl Zeiss). 30 total sections were 
taken at a 0.36 µm intervals in the z-axis. 3D deconvolution was performed using algorithms in 
AutoQuant X 3.0.1 software (Media Cybernetics). Z-projections were generated by summing 
individual sections in ImageJ 1.48v.   
 For scanning electron microscopy of retracted clots, clots were washed in HBS, fixed in 2% 
paraformaldehyde, 2.5% glutaraldehyde, and 0.15 M sodium phosphate, pH 7.4, and stored at 
4°C. Fixed clots were bisected longitudinally and dehydrated with a graded ethanol series (30%, 
50%, 75%, 90%, and 100% [three times], each for 20 minutes). Clots were critical point-dried, 
sputter-coated with gold/palladium using a Hummer X sputter coater (Anatech), and viewed 
using a Zeiss Supra 25 Field Emission Scanning Electron Microscope (Carl Zeiss) with a 5 kV 
accelerating voltage and 20 µm aperture. Three random points on each clot were imaged at 
5010X magnification. To determine fibrin network density, a 5X6 grid was overlaid on each 
image in Adobe Photoshop CS6 and the number of grid intersections that appeared over a fiber 
was counted (fibers/point). 
 
 Fibrin band shift assay. Citrated whole blood or PRP was clotted with thrombin (20 nM, 
final) and recalcification (5 mM CaCl2, final) in the absence or presence of T101 (200 µM, final) 
for 2 hours at 37°C. Clots were then separated from serum by centrifugation (250xg, 15 
minutes). Cells were lysed and clots washed by incubation in 1X Cell Lysis Buffer (Cell 
Signaling) with 1 mM phenylmethylsulfonyl fluoride (MP Biomedicals), followed by 
homogenization and washing with distilled water. Clots were subsequently dissolved in 50 mM 
dithiothreitol/12.5 mM EDTA in 8 M urea (DTT/EDTA/urea) at 60°C for 1 hour. Samples were 
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boiled in SDS-containing sample buffer and separated using SDS-PAGE on 10% Tris-glycine 
gels. 
 
 FXIIIa substrate crosslinking to RBCs. RBCs were isolated from citrated whole blood by 
centrifugation (150xg, 20 minutes), washed in citrate-glucose-saline, and packed as described.18 
Packed RBCs (10 µL) were incubated with a Cy5-labeled peptide derived from the amino-
terminus of α2-antiplasmin (A15, Ac-GNQEQVSPLTLLKWC[Cy5]-NH2, 3 µM, final)22 or 
biotinylated cadaverine (BC, 5 mM, final) in the presence of FXIII-A2B2 (20 µg/mL, final), 
thrombin (5 nM, final), and CaCl2 (10 mM, final), rotating for 1 hour (40 µL, final volume). 
Control samples contained 0.5 mg/mL Peak 1 fibrinogen, and no RBCs. For SDS-PAGE, 
reactions were quenched and dissolved in DTT/EDTA/urea, boiled, and separated on 10% Tris-
glycine gels. A15-crosslinked species were directly visualized on a GE Typhoon FLA-9000 
Imager (GE Healthcare). Gels of BC samples were transferred to PVDF membranes and probed 
with 0.2 µg/mL Alexa Fluor® 488-labeled streptavidin before visualization on the Typhoon 
Imager. For flow cytometry, samples were diluted 1:200 in flow buffer (21 mM Tris [pH 7.4], 
140 mM NaCl, 11.1 mM dextrose, 4.7 mM KCl, 1.2 mM MgSO4, and 0.1% PEG 8000) and 
labeled with phycoerythrin-labeled anti-CD235a. Samples containing BC were also labeled with 
Alexa Fluor® 488-labeled streptavidin. Samples were diluted in flow buffer and analyzed using a 
Stratedigm S1000Ex flow cytometer. 
 
 Murine blood clot contraction. Blood was drawn into citrate from the inferior vena cava of 
anesthetized wild-type, α2-antiplasmin-deficient23, and thrombin-activatable fibrinolysis inhibitor 
(TAFI)-deficient24 mice, or Fnfl/fl Mx Cre- (pFn+) and Fnfl/fl Mx Cre+(pFn-) mice25. Plasma 
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fibronectin (pFn) depletion was induced by three intraperitoneal injections of 250 µg of 
polyinonic-polycytidylic acid (Sigma) into Cre+ and Cre- littermates at two-day intervals. 
Depletion of pFn in plasma and platelets was confirmed by Western blotting. For wild-type, α2-
antiplasmin-deficient, and TAFI-deficient mice, blood was pooled from 6-9 mice before clotting. 
For pFn+ and pFn- mice, blood from 6-9 separate mice was studied. Blood was added whole or 
diluted 1:3 in HBS to siliconized tubes containing TF (1 pM, final) and CaCl2 (10 mM, final), as 
described.18 FXIIIa was inhibited with T101 (5 µM, final). Serum RBC content was measured by 
absorbance (575 nm). 
 
 Isolation of differentially-aged RBC populations. RBCs were separated into three fractions 
using density gradient centrifugation, as described.26 Briefly, blood was collected into acid-
citrate-dextrose and separated by centrifugation (800xg, 15 minutes). Packed RBCs were 
resuspended in RPMI to 50% hematocrit and lymphocytes were removed using a 2:1 (w/w) α-
cellulose/microcrystalline cellulose column. RBCs were then washed twice with 10 mM HEPES, 
12 mM NaCl, 115 mM KCl, 5% BSA. After washing, RBCs were centrifuged (1075xg, 25 
minutes) against a discontinuous Percoll gradient (65, 60, 55, and 50%). Following isolation, 
each fraction was washed twice and stored at 4°C for up to 24 hours before reconstitution in PRP 
for use in clot retraction experiments. 
 
 Recombinant fibrinogen generation. Recombinant fibrinogen variants were expressed and 
purified as described.15,27,28 Briefly, Chinese hamster ovary cells engineered to express wild-type 
fibrinogen (γA/γA)27, or fibrinogen with mutations that remove γ-chain crosslinking sites 
(γQ398N/Q399N/K406R, γNNR15) or truncate the α-chain (Aα25128), were grown in roller 
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bottles at 37 °C in serum-free DMEM/F12 50/50 supplemented with insulin-transferrin-sodium 
selenite (10 µg/mL, Roche Basel, Switzerland) and aprotinin (10 U/mL, Sigma). Conditioned 
media was harvested, treated with phenylmethylsulfonyl fluoride (150 µM) and stored at -20 °C 
until purification. Fibrinogen was purified by ammonium sulfate precipitation and 
immunoaffinity chromatography as previously described.15,28 Compared to γA/γA fibrinogen, 
recombinant fibrinogen variants clotted with similar onset times and rates, as expected.17,28  
 
 Western blotting. Clots were dissolved in DTT/EDTA/urea (60°C, 1 hour), boiled in SDS-
containing sample buffer, and separated using SDS-PAGE on 10% Tris-glycine gels before 
transfer to PVDF membranes. Densitometry was performed using ImageJ 1.48v. Band intensity 
of HMW species and γ-γ dimers was normalized to the β-chain before normalization to untreated 
controls. 
 
 Statistical methods. Serum RBC content and clot weights were compared using paired or 
one-tailed Student’s t-tests, as appropriate. Significance of correlations was determined by 
Pearson’s correlation coefficient. Percent changes in clot weight, network density, fiber 
thickness, probe crosslinking to RBCs, and IC50 values were compared using an unpaired, two-
tailed Student’s t-test. P<0.05 was considered statistically significant.  
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Figure 2.1. In the absence of FXIIIa activity, RBCs are extruded from the clot during clot 
contraction. (A-B) Clot formation and contraction was triggered by recalcification (10 mM, 
final) and addition of TF (1 pM, final) to whole blood spiked with octadecyl rhodamine B-
labeled RBCs, Alexa Fluor 488®-labeled fibrinogen, and ε-ACA (to inhibit fibrinolysis). Clot 
contraction was visualized on a Zeiss 710 NLO confocal laser scanning microscope with an 
incubation chamber and temperature stage (Carl Zeiss, Thornwood, NY), and monitored at 40x 
magnification. Representative frames of contracting clots formed in the absence (A) and 
presence (B) of T101 (10 µM, final). Times (in seconds) are indicated in each panel. Scale bar is 
50 µm. (C) Clot formation and contraction was triggered by addition of thrombin (1U/mL [10 
nM], final) and recalcification (10 mM, final) to whole blood. Clot contraction was visualized at 
10X with digital zoom on a Nikon Eclipse TE2000-U inverted microscope (Nikon Instruments, 
Melville, NY). Frames depict RBC extrusion from a contracting clot. Black arrowheads highlight 





 In the absence of FXIIIa activity, RBCs are extruded from the clot during clot 
contraction. We previously showed that FXIIIa promotes RBC retention in contracting clots.18 
To visualize this process, we generated whole blood clots in the presence of Alexa Fluor® 488-
labeled fibrinogen, octadecyl rhodamine B chloride-labeled RBCs, and ε-ACA (to inhibit 
fibrinolysis), in the absence and presence of the FXIIIa inhibitor, T101. We then visualized clot 
contraction using real-time confocal and differential interference contrast microscopy (Figure 
2.1). In clots with normal FXIIIa activity, most RBCs were retained within the clot (Figure 
2.1A). In contrast, inhibiting FXIIIa with T101 increased RBC mobility within the contracting 
clot and increased RBC extrusion from the clot (Figure 2.1B). In some clots, we observed 
“plumes” of RBCs being ejected from the clot. In both cases, RBCs exiting the clots exhibited 
substantial, but transient, deformation, consistent with their highly deformable nature (Figure 
2.1C). Notably, RBCs resumed their characteristic discoid shape once free of the clot (Figure 
2.1C). Together with previous findings18, these images demonstrate a critical role for FXIIIa 
activity in RBC retention in clots.   
 
FXIIIa does not crosslink RBCs to fibrin. We first tested the hypothesis that FXIIIa 
directly crosslinks RBCs to fibrin. Although RBCs noncovalently bind fibrin(ogen)29-31, a 
covalent interaction between RBCs and fibrin has not been identified. To determine if FXIIIa 
crosslinks a RBC surface protein to fibrin, we analyzed fibrin in clots generated in the absence 
and presence of RBCs and FXIIIa activity. We anticipated that if FXIIIa crosslinks RBCs to 
fibrin, crosslinked fibrin formed in the presence of RBCs would migrate more slowly than fibrin 










Figure 2.2. FXIIIa does not crosslink fibrin to RBCs. Clotting was initiated in recalcified (5 
mM, final) PRP (-RBCs) or whole blood (+RBCs) with thrombin (20 nM, final), in the absence 
or presence of T101 (200 µM, final). Clots were then dissolved and fibrin crosslinking patterns 
were analyzed by Western blotting using a polyclonal anti-human fibrinogen antibody. 
Representative blot of N=4 experiments. 
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not exhibit fibrin band shifts or new bands relative to clots formed in the absence of RBCs. 
These data are consistent with prior studies that identified transglutaminase-2 substrates on the 
cytoplasmic, but not outer, surface of the RBC membrane32,33, and suggest FXIIIa does not 
crosslink RBCs to fibrin. 
 
 FXIIIa does not crosslink glutamine- or lysine-reactive substrates to RBCs. To identify 
any fibrin-independent FXIIIa substrates on RBCs, we utilized two probes for FXIIIa activity: 
A15 peptide and biotinylated cadaverine (BC). A15 peptide contains a glutamine residue 
recognized by FXIIIa22	  and BC mimics a reactive lysine substrate of FXIIIa34. Whereas FXIIIa 
efficiently crosslinked A15 (Figure 2.3A) and BC (Figure 2.3B) to fibrin, analysis of cell lysates 
of washed RBCs incubated with FXIIIa and A15 or BC did not reveal any labeled proteins 
(Figure 2.3A-B, lower limit of detection, ~300 molecules/cell, data not shown). 
 Since RBC interactions with plasma proteins can be mediated by cell membrane lipids, 
including sulfatide35, we also incubated washed RBCs with FXIIIa and A15 peptide or BC and 
analyzed intact cells using flow cytometry. Similar to findings with SDS-PAGE, we did not 
detect A15 peptide or BC on intact CD235a-positive cells (RBCs) in the absence or presence of 
FXIIIa, indicating RBCs do not have ligands for these established FXIIIa substrates (Figure 
2.3C-D). Collectively, these findings indicate FXIIIa does not promote RBC retention by 
crosslinking RBCs into the clot. 
 
 α2-antiplasmin, TAFI, and fibronectin are not required for FXIIIa-mediated RBC 
retention. Three established non-fibrin substrates of FXIIIa are α2-antiplasmin, TAFI, and 








Figure 2.3. FXIIIa does not crosslink FXIIIa substrates to RBCs. (A) Cy5-labeled A15 
peptide (glutamine donor, 3 µM, final) or (B) biotinylated cadaverine (BC, lysine acceptor, 5 
mM, final) were incubated with FXIII (20 µg/mL, final) and washed RBCs in the presence of 
thrombin (IIa, 5 nM, final) and CaCl2 (10 mM, final) to probe for reactive lysine and glutamine 
residues, respectively, on the RBC surface. RBCs were then lysed, proteins separated by SDS-
PAGE, and labeling visualized using Cy5 fluorescence (A15) or by transfer to a PVDF 
membrane and probing with Alexa Fluor® 488-labeled streptavidin. Control reactions contained 
fibrinogen (0.5 mg/mL, final), FXIII, thrombin, CaCl2, and A15 or BC. (C-D) For flow 
cytometry, intact cells were incubated with a phycoerythrin-labeled anti-human CD235a 




Figure 2.4. FXIIIa does not require α2-antiplasmin, TAFI, or fibronectin to promote RBC 
retention in clots. Serum RBC content from ex vivo clot contraction assays using whole blood 
from (A) wild-type (WT), α2-antiplasmin-deficient (α2-AP-/-), and TAFI-deficient (TAFI-/-) mice 
(N=3) or (B) fibronectin-sufficient (pFn+) and -deficient (pFn-) mice (N=6-9). Clotting was 
initiated with TF (1 pM, final) and recalcification (10 mM, final). WT and pFn+ blood was 





analyzing clot contraction of whole blood from mice deficient in these proteins. While FXIIIa 
inhibition increased RBC extrusion from wild-type mouse clots (P<0.03, Figure 2.4A-B), 
deficiency in α2-antiplasmin, TAFI, or fibronectin did not increase RBC loss (Figure 2.4A-B). 
Moreover, RBC loss was similar in wild-type blood clotted in the absence and presence of the 
fibrinolysis inhibitor ε-ACA (serum RBC content was 31.6 and 32.5% of initial, respectively). 
Together, these results show that these canonical FXIIIa substrates are not required for RBC 
retention in clots, and that the effect of FXIIIa is not due to its antifibrinolytic function. 
 
 Fibrin network density mediates RBC retention in clots only in the presence of FXIII 
activity. RBC retention in clots has traditionally been attributed to steric effects of the fibrin 
network. Therefore, we examined the effect of fibrin network density on RBC retention by 
triggering clot formation using a range of TF concentrations (1, 10, and 100 pM, final) to 
produce clots with different initial network densities20 in the absence and presence of FXIIIa 
activity (±T101) (Figure 2.5A-B). As expected, increasing the TF concentration increased fibrin 
network density in both the absence and presence of FXIIIa activity, and at each TF 
concentration, clots formed in the absence and presence of FXIIIa activity had similar network 
densities. We then correlated the TF concentration with the serum RBC content and weight of 
fully contracted whole blood clots. As predicted, increasing the concentration of TF decreased 
serum RBC content and increased clot weight (Figure 2.5C-D). However, at all TF 
concentrations tested, FXIIIa inhibition increased RBC extrusion from clots 2-4-fold (P<0.002, 
Figure 2.5C) and decreased clot weight 16-48% (P<0.0002, 2.5D), indicating an independent 
effect of FXIIIa. We also measured final fibrin network density in fully contracted whole blood 
clots. As seen in studies of plasma clots8,9, the absence or presence of FXIIIa activity (±T101) 
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Figure 2.5. FXIIIa mediates 
RBC retention independent of 
fibrin network density. (A-B) 
Recalcified (10 mM, final) 
plasma spiked with Alexa 
Fluor® 647-labeled fibrinogen 
was clotted with the indicated 
TF concentrations in the absence 
(A) or presence (B) of T101 
(200 µM, final). Images are 
representative confocal 
micrographs (z-projections of 30 
individual slices) of clots 
visualized on a Zeiss LSM710 
laser scanning confocal 
microscope with a 63X oil-
immersion lens (Carl Zeiss, 
Thornwood, NY). Scale bar is 
30 µm. (C) Serum RBC content 
and (D) clot weight following 
clot contraction. Each dot 
represents an individual clot. 
Lines connect clots formed from 
the same blood donor. 
Horizontal, dark lines indicate 
medians. (E-F) Representative 
scanning electron micrographs 
of clots formed in recalcified (10 
mM, final) whole blood with the 
indicated TF concentrations in 
the absence (E) and presence (F) 
of T101 (10 µM, final). Clots 
were visualized at 5010X on a 
Zeiss Supra 25 Field Emission 
Scanning Electron Microscope 
(Carl Zeiss, Thornwood, NY). 
Scale bar is 10 µm. Micrographs 
were used to measure fibrin 
network density, which was 
compared to the serum RBC 
content (G, I) or clot weight (H, 
J) following clot contraction in 
the absence (G, H) and presence 
(I, J) of T101. 
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did not significantly alter fibrin network density (P>0.07) or fiber thickness (P>0.10) at any TF 
concentration tested (Figure 2.5E-F). In the presence of FXIIIa activity, final fibrin network 
density was strongly, negatively correlated with serum RBC content (Figure 2.5G) and strongly, 
positively correlated with final clot weight (Figure 2.5H). Interestingly, however, these 
correlations were lost in the presence of T101 (Figure 2.5I, J), suggesting substantial structural 
heterogeneity arises in the fibrin network during the extensive RBC loss and clot contraction that 
occur in the absence of FXIIIa. These data suggest FXIIIa does not promote RBC retention in 
clots simply by increasing fibrin network density, and show independent effects of FXIIIa on 
RBC retention in contracted clots. 
 
 FXIIIa inhibition reduces RBC retention in clots lacking γ-, but not α-chain, 
crosslinking. Finally, we tested the hypothesis that FXIIIa promotes RBC retention in clots via 
its ability to crosslink fibrin. FXIIIa crosslinks residues between γ- and α-chains within fibrin 
fibers, and studies have revealed distinct effects of each type of crosslinking on the fibrin 
network.14-17,36 Therefore, we specifically interrogated the individual contributions of γ- and α-
chain crosslinks to RBC retention. 
 We first performed clot contraction assays using recombinant fibrinogens mutated to 
eliminate either γ- or α-chain crosslinking (Supplemental Figure 2.2). To test the role of γ-chain 
crosslinking, we used a fibrinogen variant (γQ398N/Q399N/K406R, γNNR15) that lacks the three 
γ-chain crosslinking residues. To test the role of α-chain crosslinking, we used fibrinogen with 
an Aα-chain truncation at residue 251 (Aα25128), which eliminates most of the α-chain 
crosslinking residues. We reconstituted fibrinogen-deficient plasma with RBCs, platelets, and 












Figure 2.6. FXIIIa inhibition does not reduce RBC retention in clots formed with Aα251 
fibrinogen. Percent reduction in clot weight of contracted clots formed from TF-treated, 
recalcified fibrinogen-deficient plasma reconstituted with RBCs and platelets (2 million/µL and 
200,000/µL, respectively), and γA/γA, γNNR, or Aα251 fibrinogen (0.25 mg/mL, final), in the 
absence or presence of 10 µM (final) T101 (N=3-7 per fibrinogen). Bars are means ± SE. 
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presence of T101. Figure 2.6 shows the percent reduction in clot weight caused by the presence 
of T101 for each variant. FXIIIa inhibition significantly reduced the size of clots formed with 
γA/γA fibrinogen (3.3±0.5 versus 1.2±0.3 mg, respectively, P<0.001) and γNNR (3.7±0.5 versus 
1.6±0.4 mg, respectively, P<0.01). These data indicate γ-chain crosslinking is not required for 
RBC retention in contracted clots. In contrast, inhibiting FXIIIa in clots formed with Aα251 did 
not reduce clot size (7.9±0.6 versus 7.7±0.6 mg, respectively, P=0.3). Since clots formed from 
Aα251 were larger than those formed from γA/γA and γNNR fibrinogens, likely due to the 
abnormal fibrin network structure previously reported for this variant36, we also measured RBC 
retention in clots formed from lower concentrations of Aα251 fibrinogen (0.125 mg/mL, final). 
While reducing fibrin concentration reduced clot weight, these clots still failed to show an effect 
of FXIIIa inhibition on clot weight (data not shown).    
To further test the contributions of γ- and α-chain crosslinking in RBC retention, we 
exploited previous observations that low concentrations of FXIIIa inhibitors selectively inhibit 
formation of HMW α-chain-rich crosslinked species without reducing γ-γ dimer formation.14,37 
We generated plasma clots in the presence of a range of T101 concentrations (0-200 µM), 
dissolved the clots, and probed for fibrin crosslinking via Western blotting (Figure 2.7A). 
Consistent with the previous studies14,37, T101 inhibited HMW species formation at ~40-fold 
lower concentrations than it inhibited γ-γ dimer formation (IC50 = 0.52±0.12 versus 21.1±5.8 µM, 
respectively, P<0.03, Figure 2.7B). Importantly, when we superimposed the effects of T101 on 
fibrin crosslinking, clot weight, and RBC retention, we found that T101 reduced clot weight 
(IC50 = 0.60±0.09 µM, Figure 2.7B) and RBC retention (not shown) at the same concentrations at 
which it inhibited HMW species formation (Figure 2.7B). Together, these data show FXIIIa 
promotes RBC retention in clots by crosslinking fibrin α-chains. 
 39 
Figure 2.7. RBC retention is reduced at concentrations of T101 that inhibit α-chain 
crosslinking. (A) Recalcified (10 mM, final) plasma was clotted with TF (1 pM) in the presence 
of increasing concentrations of T101. Clots were dissolved and analyzed by Western blotting 
with polyclonal anti-human fibrinogen antibody. (B) Normalized intensity of γ-γ dimer (open 
diamonds, short dashed line, N=3) or HMW bands (open squares, long dashed line, N=3) 
superimposed on normalized clot weight following clot contraction in the presence of T101 










The importance of FXIII activity in stabilizing clots is well-established. However, the recent 
recognition of FXIII’s essential role in determining thrombus composition and size18 raises 
important questions about its contributions to clot formation in vivo. Our study to determine the 
mechanism mediating RBC retention in clots reveals previously unrecognized functions for 
FXIIIa activity and fibrin crosslinking. We showed RBC retention is not mediated by direct 
crosslinking of RBCs to the clot, but is increased by increased fibrin network density in the 
presence, but not absence, of FXIIIa activity. This finding demonstrates an essential role of 
crosslinked fibrin in determining thrombus cellular content. Importantly, we found that FXIIIa 
crosslinking of fibrin α-chains promoted RBC retention in clots. Although previous studies have 
documented unique, independent contributions of α- and γ-chain crosslinking to fibrin 
biophysical characteristics14-17,36, our findings are the first to associate these characteristics with 
a specific function during thrombus formation in vivo. The findings presented here define the 
mechanism by which FXIIIa mediates thrombus composition and expose a newly-recognized, 
essential (patho)physiologic function for fibrin crosslinking. 
 It has traditionally been thought that the fibrin network functions like a net that traps and 
retains RBCs flowing by the developing clot. Our findings support, but substantially refine, this 
concept. We observed that in a normally-crosslinked clot, RBC retention is strongly associated 
with fibrin network density. Fibrin network density is mediated by several factors, including the 
concentrations of fibrinogen and thrombin present during fibrin formation (reviewed in 38). We 
and others have shown that plasma hypercoagulability results in the formation of clots with high 
fibrin network density.39-44 It is tempting to speculate that these dense networks trap more RBCs, 
resulting in large, occlusive venous thrombi. Indeed, we previously observed that 
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hyperprothrombinemia leads to the formation of clots with increased network density45 and that 
mice with elevated prothrombin produce significantly larger venous thrombi39 that have higher 
RBC content (Aleman and Wolberg, unpublished observation). Together, these findings suggest 
an abnormally high density of crosslinked fibrin promotes venous occlusion by increasing RBC 
retention in the thrombus, and therefore, thrombus size.  
 The relationship between network density and RBC retention was lost in un-crosslinked 
clots. Since we and others have observed little-to-no effect of fibrin crosslinking on network 
density8,9, increased RBC extrusion from un-crosslinked clots is unlikely to be due to abnormal 
network density. Rather, these data support the premise that FXIIIa’s effects on clot biophysical 
properties mediate RBC retention in the clots. Previous studies have demonstrated distinct 
contributions of γ- and α-chain crosslinking to fibrin viscoelastic properties. Using a synthetic 
inhibitor and patient-derived anti-FXIII antibody, Ryan et al. showed that the FXIIIa-mediated 
increase in clot stiffness correlates with the generation of α-chain-rich HMW species and not 
with γ-γ dimers.14 Furthermore, only partial α-chain crosslinking was required to reach near-
maximal clot stiffness14, consistent with our observation that even partial crosslinking of α-
monomers increased RBC retention. More recently, Collet et al. used recombinant Aα251 
fibrinogen to show that clots with only γ-chain crosslinking are nearly 4-times less stiff than γ- 
and α-chain crosslinked clots.36 Similarly, studies using γNNR fibrin (only α-chain crosslinking) 
showed the majority of the stiffness of fully-crosslinked clots is provided by α-chain 
crosslinking.15-17 Consequently, our observation that α-chain crosslinking mediates FXIIIa-
mediated RBC retention in clots identifies a potential (patho)physiologic consequence of α-chain 
crosslinking and fibrin fiber stiffening during clot formation in vivo.  
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 The observation that γ- and α-chain crosslinking is inhibited by different concentrations of 
inhibitor14,37 may suggest a conformational change in FXIIIa facilitates γ- versus α-chain 
crosslinking, and that the α-chain-specific conformation is more susceptible to inhibition than the 
γ-specific conformation. Alternately, the spatial relationship between FXIIIa and the γ- and α-
chains during FXIII activation may contribute to differential timing and inhibition of γ- and α-
chain crosslinking. We recently localized FXIII zymogen binding to the homologous murine γ-
chain residues 390-39618, which would conveniently position activated FXIIIa near the γ-chain 
crosslinking sites (γ398/399/406). Thus, the rate of γ-chain crosslinking may exceed α-chain 
crosslinking due to the proximity of FXIII(a) to the γ-chain after activation. Whether these 
differences can be exploited to evaluate γ- versus α-chain crosslinking in vivo remains to be 
determined. 
 Although previous studies demonstrated specific interactions between fibrin and RBCs29-31, 
and implicate CD4746 and a β3-like molecule47 on the RBC surface, we were unable to detect 
any FXIIIa substrates on the RBC surface. We were also unable to detect differences in retention 
of young versus old RBCs in clots (data not shown), indicating age-dependent changes in RBC 
protein expression or morphology48 do not influence their presence in clots. These data suggest 
FXIIIa does not covalently ligate RBCs to the clot. This finding is somewhat surprising, since a 
recent report suggested FXIIIa is highly promiscuous, with over 147 potential substrates in 
plasma.49 However, our findings are consistent with a previous study that also did not identify 
any transglutaminase substrates on the RBC surface.32 Together, these results indicate FXIIIa 
retains considerable substrate specificity during coagulation in whole blood. 
 The consequences of RBC retention in clots is an area of active investigation. Clot 
contraction induces the appearance of compacted RBCs (so-called “polyhedrocytes”).50 This 
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observation demonstrates substantial platelet-mediated forces are transmitted through the clot 
during contraction51,52 and suggests the fibrin network must be sufficiently dense and stiff to 
retain RBCs during this process. The contribution of crosslinking to fibrin elasticity, 
extensibility, and stiffness occurs at both whole-clot and single-fiber scales.10-14 In addition to 
clot contraction, shear stress from blood flow in vivo also exerts considerable force onto the 
fibrin network. Thus, in the absence of FXIIIa-mediated crosslinking, fibrin may deform or even 
break, permitting RBCs to escape. Further studies examining the contributions of crosslinked 
fibrin, as well as platelet contractile force and RBC deformability, to clot formation are needed 
to fully define the how α-chain crosslinking mediates RBC retention in clots. 
 This study has potential limitations. First, although we did not identify FXIIIa substrates on 
the RBC surface, our lower limit of detection was ~300 molecules/cell. However, it would be 
surprising if a protein present at lower copy number could effectively promote RBC retention 
within the clot. Second, fibrin crosslinking could generate a neoepitope that promotes RBC 
binding and retention; however, we did not observe substantial differences in RBC binding to 
fibrin in the absence and presence of FXIIIa. Third, Aα251 exhibits slightly delayed 
crosslinking36, which may have reduced the effect of FXIIIa. However, results from experiments 
with recombinant fibrinogens were consistent with findings using full-length fibrinogen in 
plasma, and support the conclusion that α-chain crosslinking mediates RBC retention. Finally, 
our experiments were performed under static conditions. Although stasis recapitulates aspects of 
VT53, other mechanisms may mediate RBC content in clots formed under higher (arterial) shear.  
 In summary, our results show FXIIIa promotes RBC retention in clots by crosslinking fibrin. 
Formation of α-chain-rich, HMW crosslinked fibrin species correlated strongly with RBC 
retention in clots, suggesting biophysical strengthening of the fibrin network secondary to α-
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chain crosslinking determines clot composition. Overall, these findings refine our understanding 
of the FXIII-fibrinogen axis and establish α-chain crosslinking as a potential therapeutic target 
for reducing VT. 
2.6. Supplemental figures. 
 
	    
	  
Supplemental Figure 2.1. Plasma from 
the fibrinogen-deficient patient lacks 
all three fibrinogen chains. 
Representative Western blot of 
fibrinogen content in normal pooled 
plasma (NPP) and fibrinogen-deficient 
patient plasma. Fibrinogen chains were 




Supplemental Figure 2.2. Recombinant 
γA/γA, γNNR, and Aα251 fibrinogen 
preparations are pure and contain intact 
Aα-, Bβ-, and γ-chains. Recombinant 
fibrinogens were expressed and purified as 
described.1-3 Samples were boiled in 6X 
Laemmli sample buffer containing sodium 
dodecyl sulfate and β-mercaptoethanol, 
separated by SDS-PAGE, and stained with 
Coomassie brilliant blue. The α-, β- and γ- 




1. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler 
Thromb Vasc Biol. 2011;31(3):494-499. 
	  
2. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 
patients with inherited afibrinogenaemia. Br J Haematol. 1999;107(1):204-206. 
 
3. Wilhelmsen L, Svardsudd K, Korsanbengtsen K, Larsson B, Welin L, Tibblin G. 
Fibrinogen as a risk factor for stroke and myocardial-infarction. New England Journal of 
Medicine. 1984;311(8):501-505. 
 
4. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. 
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not 
caused by acute phase reactions. Thromb Haemost. 1999;81(5):680-683. 
 
5. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. 
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control 
study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study 
(LETS). Thromb Haemost. 1994;71(6):719-722. 
 
6. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation 
factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931-972. 
 
7. Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost. 
2013;39(6):632-641. 
 
8. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. 
Biophys J. 1999;77(5):2813-2826. 
 
9. Hethershaw EL, Cilia La Corte AL, Duval C, Ali M, Grant PJ, Ariens RA, Philippou H. 
The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J 
Thromb Haemost. 2014;12(2):197-205. 
 
10. Glover CJ, McIntire LV, Brown CH, 3rd, Natelson EA. Rheological properties of fibrin 
clots. Effects of fibrinogen concentration, factor XIII deficiency, and factor XIII 
inhibition. J Lab Clin Med. 1975;86(4):644-656. 
 
11. Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual fibrin 
fiber in a clot. Proc Natl Acad Sci U S A. 2005;102(26):9133-9137. 
 
12. Liu W, Jawerth LM, Sparks EA, Falvo MR, Hantgan RR, Superfine R, Lord ST, Guthold 




13. Liu W, Carlisle CR, Sparks EA, Guthold M. The mechanical properties of single fibrin 
fibers. J Thromb Haemost. 2010;8(5):1030-1036. 
 
14. Ryan EA, Mockros LF, Stern AM, Lorand L. Influence of a natural and a synthetic 
inhibitor of factor XIIIa on fibrin clot rheology. Biophys J. 1999;77(5):2827-2836. 
 
15. Standeven KF, Carter AM, Grant PJ, Weisel JW, Chernysh I, Masova L, Lord ST, Ariens 
RA. Functional analysis of fibrin γ-chain cross-linking by activated factor XIII: 
determination of a cross-linking pattern that maximizes clot stiffness. Blood. 
2007;110(3):902-907. 
 
16. Helms CC, Ariens RA, Uitte de Willige S, Standeven KF, Guthold M. α-α cross-links 
increase fibrin fiber elasticity and stiffness. Biophys J. 2012;102(1):168-175. 
 
17. Duval C, Allan P, Connell SD, Ridger VC, Philippou H, Ariens RA. Roles of fibrin α- 
and γ-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb 
Haemost. 2014;111(5):842-850. 
 
18. Aleman MM, Byrnes JR, Wang JG, Tran R, Lam WA, Di Paola J, Mackman N, Degen 
JL, Flick MJ, Wolberg AS. Factor XIII activity mediates red blood cell retention in 
venous thrombi. J Clin Invest. 2014;124(8):3590-3600. 
 
19. Machlus KR, Colby EA, Wu JR, Koch GG, Key NS, Wolberg AS. Effects of tissue 
factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the 
calibrated automated thrombogram. Thromb Haemost. 2009;102(5):936-944. 
 
20. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of 
extravascular and intravascular cells to fibrin network formation, structure, and stability. 
Blood. 2009;114(23):4886-4896. 
 
21. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose 
factor VIIa improves clot structure and stability in a model of haemophilia B. Br J 
Haematol. 2005;131(5):645-655. 
 
22. Tung CH, Ho NH, Zeng Q, Tang Y, Jaffer FA, Reed GL, Weissleder R. Novel factor 
XIII probes for blood coagulation imaging. Chembiochem. 2003;4(9):897-899. 
 
23. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. alpha(2)-antiplasmin gene 
deficiency in mice is associated with enhanced fibrinolytic potential without overt 
bleeding. Blood. 1999;93(7):2274-2281. 
 
24. te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel Rinkes IH, Voest EE, 
Bouma BN, Gebbink MF, Meijers JC. Impaired healing of cutaneous wounds and colonic 
anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb 
Haemost. 2003;1(10):2087-2096. 
 47 
25. Wang Y, Reheman A, Spring CM, Kalantari J, Marshall AH, Wolberg AS, Gross PL, 
Weitz JI, Rand ML, Mosher DF, Freedman J, Ni H. Plasma fibronectin supports 
hemostasis and regulates thrombosis. J Clin Invest. 2014;124(10):4281-4293. 
 
26. Clark MA, Goheen MM, Fulford A, Prentice AM, Elnagheeb MA, Patel J, Fisher N, 
Taylor SM, Kasthuri RS, Cerami C. Host iron status and iron supplementation mediate 
susceptibility to erythrocytic stage Plasmodium falciparum. Nat Commun. 2014;5:4446. 
 
27. Lord ST, Binnie CG, Hettasch JM, Strickland E. Purification and characterization of 
recombinant human fibrinogen. Blood Coagul Fibrinolysis. 1993;4(1):55-59. 
 
28. Gorkun OV, Henschen-Edman AH, Ping LF, Lord ST. Analysis of Aα251 fibrinogen: the 
αC domain has a role in polymerization, albeit more subtle than anticipated from the 
analogous proteolytic fragment X. Biochemistry. 1998;37(44):15434-15441. 
 
29. Rampling MW. The binding of fibrinogen and fibrinogen degradation products to the 
erythrocyte membrane and its relationship to haemorheology. Acta Biol Med Ger. 
1981;40(4-5):373-378. 
 
30. Maeda N, Seike M, Kume S, Takaku T, Shiga T. Fibrinogen-induced erythrocyte 
aggregation: erythrocyte-binding site in the fibrinogen molecule. Biochim Biophys Acta. 
1987;904(1):81-91. 
 
31. Lominadze D, Dean WL. Involvement of fibrinogen specific binding in erythrocyte 
aggregation. FEBS Lett. 2002;517(1-3):41-44. 
 
32. Dutton A, Singer SJ. Crosslinking and labeling of membrane proteins by 
transglutaminase-catalyzed reactions. Proc Natl Acad Sci U S A. 1975;72(7):2568-2571. 
 
33. Lorand L, Shishido R, Parameswaran KN, Steck TL. Modification of human erythrocyte 
ghosts with transglutaminase. Biochem Biophys Res Commun. 1975;67(3):1158-1166. 
 
34. Lorand L, Chenoweth D, Gray A. Titration of the acceptor cross-linking sites in fibrin. 
Ann N Y Acad Sci. 1972;202:155-171. 
 
35. Zhou Z, Thiagarajan P, Udden M, Lopez JA, Guchhait P. Erythrocyte membrane 
sulfatide plays a crucial role in the adhesion of sickle erythrocytes to endothelium. 
Thromb Haemost. 2011;105(6):1046-1052. 
 
36. Collet JP, Moen JL, Veklich YI, Gorkun OV, Lord ST, Montalescot G, Weisel JW. The 
αC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, 
and its susceptibility to fibrinolysis. Blood. 2005;106(12):3824-3830. 
 
37. Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin 
clots by causing fiber compaction. J Thromb Haemost. 2014;12(10):1687-1696. 
 48 
38. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21(3):131-
142. 
 
39. Aleman MM, Walton BL, Byrnes JR, Wang JG, Heisler MJ, Machlus KR, Cooley BC, 
Wolberg AS. Elevated prothrombin promotes venous, but not arterial, thrombosis in 
mice. Arterioscler Thromb Vasc Biol. 2013;33(8):1829-1836. 
 
40. Machlus KR, Lin FC, Wolberg AS. Procoagulant activity induced by vascular injury 
determines contribution of elevated factor VIII to thrombosis and thrombus stability in 
mice. Blood. 2011;118(14):3960-3968. 
 
41. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between 
hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 
2011;117(18):4953-4963. 
 
42. Elgue G, Sanchez J, Fatah K, Olsson P, Blomback B. The effect of plasma antithrombin 
concentration on thrombin generation and fibrin gel structure. Thromb Res. 
1994;75(2):203-212. 
 
43. Konieczynska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 2 diabetes is 
associated with increased thrombin generation, prothrombotic fibrin clot phenotype and 
impaired fibrinolysis. Thromb Haemost. 2014;111(4):685-693. 
 
44. Gronostaj K, Richter P, Nowak W, Undas A. Altered plasma fibrin clot properties in 
patients with digestive tract cancers: links with the increased thrombin generation. 
Thromb Res. 2013;131(3):262-267. 
 
45. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in 
clots with an altered fiber structure: a possible mechanism of the increased thrombotic 
risk. Blood. 2003;101(8):3008-3013. 
 
46. De Oliveira S, Vitorino de Almeida V, Calado A, Rosario HS, Saldanha C. Integrin-
associated protein (CD47) is a putative mediator for soluble fibrinogen interaction with 
human red blood cells membrane. Biochim Biophys Acta. 2012;1818(3):481-490. 
 
47. Carvalho FA, Connell S, Miltenberger-Miltenyi G, Pereira SV, Tavares A, Ariens RA, 
Santos NC. Atomic force microscopy-based molecular recognition of a fibrinogen 
receptor on human erythrocytes. ACS Nano. 2010;4(8):4609-4620. 
 
48. Franco RS, Puchulu-Campanella ME, Barber LA, Palascak MB, Joiner CH, Low PS, 
Cohen RM. Changes in the properties of normal human red blood cells during in vivo 
aging. Am J Hematol. 2013;88(1):44-51. 
 
49. Nikolajsen CL, Dyrlund TF, Poulsen ET, Enghild JJ, Scavenius C. Coagulation factor 
XIIIa substrates in human plasma: identification and incorporation into the clot. J Biol 
Chem. 2014;289(10):6526-6534. 
 49 
50. Cines DB, Lebedeva T, Nagaswami C, Hayes V, Massefski W, Litvinov RI, Rauova L, 
Lowery TJ, Weisel JW. Clot contraction: compression of erythrocytes into tightly packed 
polyhedra and redistribution of platelets and fibrin. Blood. 2014;123(10):1593-1603. 
 
51. Liang XM, Han SJ, Reems JA, Gao D, Sniadecki NJ. Platelet retraction force 
measurements using flexible post force sensors. Lab Chip. 2010;10(8):991-998. 
 
52. Lam WA, Chaudhuri O, Crow A, Webster KD, Li TD, Kita A, Huang J, Fletcher DA. 
Mechanics and contraction dynamics of single platelets and implications for clot 
stiffening. Nat Mater. 2011;10(1):61-66. 
 
53. Wolberg AS, Rosendaal FR, Weitz JI, Jaffer IH, Agnelli G, Baglin T, Mackman N. 




CHAPTER 3: THE INTERACTION BETWEEN FIBRINOGEN AND ZYMOGEN FXIII-





 The coagulation transglutaminase factor XIII (FXIII) exists in circulation as the 
heterotetrameric proenzyme FXIII-A2B2. Effectively all FXIII-A2B2 circulates bound to 
fibrinogen, and excess FXIII-B2 circulates in plasma. The motifs that mediate interaction of 
FXIII-A2B2 with fibrinogen have been elusive. We recently detected reduced binding of FXIII-
A2B2 to murine fibrinogen that has γ-chain residues 390-396 mutated to alanines (Fibγ390-396A). 
Here, we evaluated binding features using human components, including recombinant fibrinogen 
variants, FXIII-A2B2, and isolated FXIII-A2 and -B2 homodimers. FXIII-A2B2 co-precipitated 
with wild-type (γA/γA), alternatively-spliced (γʹ/γʹ), and αC-truncated (Aα251) fibrinogens, 
whereas co-precipitation with human Fibγ390-396A was reduced by 75% (P<0.0001). Surface 
plasmon resonance showed γA/γA, γʹ/γʹ, and Aα251 fibrinogens bound FXIII-A2B2 with high 
affinity (nM); however, Fibγ390-396A did not bind FXIII-A2B2. These data indicate fibrinogen 
residues γ390-396 comprise the major binding motif for FXIII-A2B2. Compared to γA/γA clots, 
FXIII-A2B2 activation peptide release was 2.7-fold slower in Fibγ390-396A clots (P<0.02). 
Conversely, activation of recombinant FXIII-A2 (lacking FXIII-B2) was similar in γA/γA and 
Fibγ390-396A clots, suggesting fibrinogen residues γ390-396 accelerate FXIII-A2B2 activation in a 
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FXIII-B2-dependent mechanism. Recombinant FXIII-B2 bound γA/γA, γʹ/γʹ, and Aα251 with 
similar affinities as FXIII-A2B2, but did not bind or co-precipitate with Fibγ390-396A. FXIII-B2 
also co-precipitated with fibrinogen from FXIII-A-deficient mouse and human plasmas. 
Collectively, these data indicate that FXIII-A2B2 binds fibrinogen residues γ390-396 via the B 
subunits, and that excess plasma FXIII-B2 is not free, but rather, circulates bound to fibrinogen. 
These findings provide insight into assembly of the fibrinogen/FXIII-A2B2 complex in both 
physiologic and therapeutic situations. 
3.2 Introduction 
	  
 Factor XIII (FXIII) is a plasma protransglutaminase that circulates at 14-28 µg/mL (43-86 
nM, reviewed in 1). Zymogen FXIII is composed of two A subunits (FXIII-A2) and two carrier B 
subunits (FXIII-B2) assembled as a non-covalent heterotetramer (FXIII-A2B2). In plasma, FXIII-
A2 is tightly-associated (KD ~100 pM)2 with FXIII-B2. Excess FXIII-B2 (43-62 nM) is present in 
circulation.2,3 During coagulation, FXIII-A2B2 is activated by thrombin-mediated cleavage of an 
N-terminal, 37-amino acid activation peptide from the FXIII-A subunits (FXIII-A2ʹ). After 
activation peptide release, calcium promotes dissociation of the inhibitory FXIII-B subunits, 
yielding fully activated FXIII-A2* (FXIIIa). Once activated, FXIIIa catalyzes the formation of ε-
N-(γ-glutamyl)-lysyl crosslinks between γ- and α-chains of fibrin and between fibrin and other 
plasma proteins. Crosslinking is essential for clot mechanical and biochemical stability 
(reviewed in 1). Fibrin α-chain crosslinking also promotes red blood cell retention in venous 
thrombi and consequently, mediates thrombus composition and size.4,5 
 FXIII-A2B2 circulates in complex with fibrinogen (KD ~10 nM)6, and these proteins are 
readily co-precipitated from plasma.7 However, the fibrinogen residues that mediate binding to 
FXIII-A2B2 in humans have not been defined. Early studies suggested the alternatively-spliced 
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fibrinogen γʹ-chain contained the FXIII-A2B2 binding site.8,9 However, studies using recombinant 
fibrinogen showed that FXIII-A2B2 binds to γ- and γʹ-containing fibrinogen with similar 
affinity10, suggesting the γʹ-extension is not necessary for FXIII-A2B2 binding. More recently, 
Smith et al. observed high affinity binding of FXIII-A2B2 to a glutathione-S-transferase-fused 
peptide containing amino acid residues 371-425 of the fibrinogen αC domain.11 However, 
whether the fibrinogen αC domain fulfills the carrier function of FXIII-A2B2 remains unclear.  
 We recently observed decreased co-precipitation of FXIII-A2B2 with murine fibrinogen that 
has alanine substitutions within residues γ390-396 (NRLSIGE to AAAAAAA, Fibγ390-396A), 
suggesting these γ-chain residues mediate the FXIII-A2B2 carrier function in mice.4 Accordingly, 
Souri et al. subsequently detected binding of FXIII-A2B2 to the human fibrinogen γ-chain at 
residues C-terminal of γLys356.12 Notably, fibrinogen residues γ390-396 are highly conserved in 
mammals (NRLTIGE [human, gorilla, dog], NRLSIGD [rat], and NRLAIGE [giant panda]), 
suggesting these residues fulfill this function across species.  
 Herein, we used entirely human components, including recombinant human fibrinogen 
variants and human FXIII heterotetramers and homodimers, as well as FXIII-deficient mice, to 
define the interaction between these proteins. Our data reveal a direct interaction between human 
fibrinogen residues γ390-396 and the FXIII-B subunits, and uncover a fundamental mechanism 
mediating FXIII-fibrinogen complex assembly in blood. These data have important implications 
for both physiologic assembly of this complex in healthy individuals, and assembly in FXIII-A2-
deficient patients receiving therapeutic recombinant FXIII-A2. 
3.3 Methods 
	  
 Proteins and Materials. Anti-human fibrinogen antibody was from Dako (Carpinteria, CA) 
and AlexaFluor 488 anti-rabbit and anti-sheep secondary antibodies were from Jackson 
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Immunoresearch (West Grove, PA). Two rabbit polyclonal anti-FXIII-B antibodies were used: 
HPA003827 (Sigma Aldrich, St. Louis, MO) and A074 (Zedira, Darmstadt, Germany), as 
indicated. Plasma FXIII-A2B2, anti-human FXIII-A antibody, and peak 1 human fibrinogen 
(FXIII-depleted) were from Enzyme Research Laboratories (ERL, South Bend, IN). 
Recombinant FXIII-A2 (rFXIII-A2) was a generous gift of Novo Nordisk (Bagsværd, Denmark). 
FXIII-A2B2 (plasma-derived) used for surface plasmon resonance and recombinant FXIII-B2 
(rFXIII-B2, produced in insect cells) were from Zedira. Insect cell-derived FXIII-B2 undergoes 
different post-translational modification than human plasma-derived FXIII-B2 and migrates 
slightly faster on SDS-PAGE. Taq polymerase was from New England Biolabs (Ipswich, MA). 
Dulbecco’s modification of Eagle’s medium/Ham’s F12, 50/50 mix was from Corning 
(Manassas, VA). Glycine was from Sigma (St. Louis, MO). Polyvinylidene fluoride membranes 
were from Millipore (Billerica, MA), 6X SDS loading dye was from Boston Bioproducts 
(Ashland, MA), and 10% Tris-glycine gels were from Bio-Rad (Hercules, CA). Murine studies 
were approved by the Institutional Animal Care and Use Committees of the Cincinnati 
Children’s Hospital Medical Center and the University of North Carolina at Chapel Hill. 
 
 Expression of recombinant fibrinogen variants. To generate recombinant Fibγ390-396A, the 
fibrinogen γ-chain expression vector pMLP-γ13,14 was used as a template to generate two 
overlapping fragments of cDNA corresponding to the C-terminal region of the γ-chain 
containing γ390-396A. The 5ʹ fragment was amplified using a forward primer containing a BstXI 
site (5ʹ-GCTGGCCATCTCAATGGAGT-3ʹ) and a reverse mutagenesis primer (5ʹ-
TTGCTGTCCAGCTGCAGCCGCAGCTGCGGCGAATGGGAT-3ʹ). The 3ʹ fragment was 
amplified using a forward mutagenesis primer (5ʹ-
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ATCCCATTCGCCGCAGCTGCGGCTGCAGCTGGACAGCAA-3ʹ) and a reverse primer 
containing a NotI site (5ʹ-GGGGCGGCCGCCCATTATAT-3ʹ). These two fragments were gel-
purified, thermally-denatured, and reannealed. The resulting hybrid fragment was extended and 
amplified using the BstXI and NotI primers before digestion with BstXI and NotI. This digested 
fragment was then ligated into BstXI- and NotI-digested pMLP-γ with T4 DNA Ligase (Thermo 
Fisher, Waltham, MA). Competent DH5α Escherichia coli were transformed with the ligated 
DNA and the γ390-396A mutation was confirmed by Sanger sequencing (Eton Bioscience, 
Research Triangle Park, NC). The pMLP-γ390-396A expression vector was then transfected into 
Chinese Hamster Ovary cells containing expression vectors for normal fibrinogen Aα- and Bβ-
chains, as previously described.14 Positive clones were identified by dot blotting with anti-human 
fibrinogen antibody. Recombinant human wild-type (γA/γA), alternatively-spliced (γʹ/γʹ), αC-
truncated (Aα251), and Fibγ390-396A (Fibγ390-396A) fibrinogen variants were then expressed in 
Chinese Hamster Ovary cells and affinity-purified as previously described.14-16 
 
 Fibrinogen precipitation experiments. Fibrinogen (1 mg/mL [2.9 µM], final) was 
incubated with FXIII-A2B2 (20 µg/mL [60 nM], final), rFXIII-A2 (10 µg/mL [60 nM], final), or 
rFXIII-B2 (10 µg/mL [63 nM], final) at room temperature for 15 minutes. Glycine (165 mg/mL) 
was then added and samples were rotated for 1 hour, after which the precipitate was pelleted by 
centrifugation (7000xg, 15 minutes) and resuspended in HEPES-buffered saline (HBS; 20 mM 
HEPES [pH 7.4], 150 mM NaCl). Fibrinogen, FXIII-A, and FXIII-B content of the initial 
sample, pellet, and supernatant were assessed by Western blotting under reducing conditions, 
unless otherwise specified. Briefly, samples were separated by SDS-PAGE on 10% Tris-Glycine 
gels, transferred to polyvinylidene fluoride membranes, and probed with primary antibodies 
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(rabbit anti-human fibrinogen [1:7000], sheep anti-human FXIII-A [1:1000], or rabbit anti-
human FXIII-B [HPA003827, 1:500]) overnight at 4°C before incubation with fluorescently-
labeled secondary antibodies for 1 hour at room temperature. Blots were visualized using a 
Typhoon FLA9000 Imager (GE Healthcare, Little Chalfont, UK). Densitometry was performed 
with ImageJ 1.48v. Percentage of FXIII-A or FXIII-B in the pellet was determined by dividing 
the intensity of the subunit band in the pellet by the sum of the band intensities in both the pellet 
and the supernatant. 
 For experiments with mouse plasma, blood was drawn via the inferior vena cava and 
processed to platelet-poor plasma by centrifugation (5000xg, 10 minutes). Fibrinogen was 
isolated from wild-type (F13a+/+), heterozygous (F13a+/-), FXIII-deficient (F13a-/-)4,17, or 
afibrinogenemic18 mouse plasma by glycine precipitation4. For experiments with 
immunodepleted human plasma (Affinity Biologicals, Ancaster, ON, lacks both FXIII-A and 
FXIII-B), plasma was first reconstituted with 10 µg/mL rFXIII-B2 and diluted three-fold prior to 
glycine precipitation. Precipitated fibrinogen and FXIII-A were detected as above. Both murine 
and human FXIII-B were detected using anti-human FXIII-B antibody (A074, 1:1000 overnight 
at room temperature). 
 
 Surface plasmon resonance (SPR) using Taylor dispersion injections. SPR was 
performed using a OneStep® titration function based on Taylor dispersion injection (TDi) 
theory.19,20 Compared to traditional (fixed concentration) injections that record analyte binding 
with respect to injection time of a series of samples of different concentrations, TDi analyzes a 
continuous analyte concentration gradient formed after a single injection in a capillary tube 
before the sample enters the SPR detector. This approach encodes a second, independent time 
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domain into an analyte gradient, which permits the use of a single binding curve that does not 
need to reach steady-state to obtain binding affinities. Thus, compared to fixed concentration 
injections, OneStep® titration reduces the time required to analyze a given analyte, lowers the 
dependence of parameters on one another and on experimental variability, increases resolving 
power, and enables analysis of interactions from a fewer number of injections. This approach 
was particularly important for analyzing high concentrations of limited amounts of recombinant 
fibrinogen variants. 
 
 Preparation of SPR analytes. FXIII ligands and fibrinogen analytes were dialyzed into 
running buffer at 4°C for 16 hours with rotation and one buffer change. Dialysis was performed 
in a volume 10,000-times that of the ligand volume using a Slide-A-Lyzer® MINI dialysis unit 
(molecular weight cutoff 7,000 Daltons, Life Technologies, Grand Island, NY). Protein 
concentration was determined using a Nanodrop1000 (Thermo Fisher, Waltham, MA).  
 A COOH-V chip (SensiQ Technologies, Oklahoma City, OK) was installed into a SensiQ 
Pioneer platform per the manufacturer’s instructions and the prime function was performed three 
times using filter-sterilized, degassed running buffer (10 mM HEPES, 140 mM NaCl, 0.05% 
Tween-20, pH 7.4). The chip surface was preconditioned for adsorption by injecting 2 bursts 
each of 10 mM HCl, 50 mM NaOH and 0.1% SDS (100 µL/min, 10 seconds). The chip was 
primed a further 3 times using running buffer. All chips were checked to ensure they were 
aligned for each flow channel; if they were not well aligned a normalize function was performed 
using 100% DMSO, followed by 3 prime steps. The chip surface was then activated by injecting 
a 50:50 solution of EDC/NHS (25 µL/min, 4 minutes), resulting in o-acylisourea active ester 
groups. The dialyzed FXIII ligands were flowed across the activated chip surface at 5 µL/min 
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flow rate at minimum concentration of 50 µg/mL, diluted into 10 mM sodium acetate with a pH 
one order of magnitude lower than the pI of the protein. The target ligands were allowed to 
couple to the active esters via primary amine groups until an RMAX of at least 50 was reached 
according to Equation 1. Any uncoupled ester groups were blocked by injecting ethanolamine 
(20 µL/minute, 5 minutes). Each protein target was immobilized on either flow-channel (FC) 1 







  ×𝑅!  ×  𝑆! 
Where:  
RMAX = The maximum binding capacity assigned between the immobilized ligand and the 
analyte, in resonance units (RU) 
Mw Analyte = Molecular mass of the molecule in solution in Daltons 
Mw Ligand = Molecular mass of the immobilized ligand in Daltons 
RL = Immobilized ligand, in RU 
SM = Predicted molecular stoichiometry of analyte to ligand 
 
Prior to analyte injections, the chip matrix was conditioned for regeneration using 3 bursts 
each of 1, 2, and 3 M NaCl (30 µL/min for 2 minutes), interspersed with 3 bursts of running 
buffer (10 mM HEPES [pH 7.4], 140 mM NaCl, 1.5 mM CaCl2) at the same rate. Salt was 
washed from the chip using 3 bursts of running buffer (30 µL/min for 2 minutes), and the loops 
were purged 3 times. All kinetic binding assays were performed with both the analysis and 




 SPR of FXIII-fibrinogen interactions. Fibrinogen analytes were diluted to 50 nM or 1 µM 
using the same batch of running buffer for blanks and the SensiQ Pioneer OneStep® titration 
function. Fibrinogen analytes were injected into the sensor chamber at a flow-rate of 30 µL/min 
using the OneStep® titration function19,20 with a loop-inject of 75% following 5 leadoff blanks 
and 3 bulk standard injections of 3% sucrose in running buffer. The 50 nM and 1 µM samples 
had dissociation times of 500 and 1000 seconds, respectively. The chip surface was regenerated 
with 2 M NaCl (30 µL/min, 60 seconds), followed by 3 M NaCl (30 µL/min, 60 seconds).  
 Data were analyzed with Qdat data analysis software (SensiQ Technologies Inc., Oklahoma 
City, OK). Binding data were fit using a simple ka/kd model and aggregation/retention 
parameters adjusted per binding curve according to goodness of fit and curve type. Sensorgrams 
from experiments with 50 nM fibrinogen analytes (maximum) recognized one binding site and 
were fit using a one-site model. Sensorgrams with 1 µM fibrinogen analyte (maximum) 
identified two binding sites for some FXIII ligands, so these data were fit using a two-site 
binding model; however, given the plasma concentrations of FXIII-A2B2 and fibrinogen, 
affinities for the second binding sites (0.7-21 µM) were considered too weak to be 
physiologically-relevant and are not reported. 
 
 FXIII activation and fibrin crosslinking. FXIII-A2B2 (20 µg/mL [60 nM], final) or rFXIII-
A2 (10 µg/mL [60 nM], final) were incubated with fibrinogen (0.15 mg/mL [440 nM], final) at 
room temperature for 15 minutes. Reactions were triggered with thrombin (2 nM, final) and 
calcium (10 mM, final). This low thrombin concentration enabled us to detect early FXIII 
activation and fibrin crosslinking. Reactions were quenched and clots dissolved with 50 mM 
dithiothreitol/12.5 mM EDTA in 8 M urea (60°C, 1 hour). Samples were boiled in SDS-
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containing sample buffer and separated using SDS-PAGE on 10% Tris-glycine gels before 
transfer to polyvinylidene fluoride membranes. Membranes were probed with primary antibodies 
(sheep anti-human FXIII-A [1:1000] or rabbit anti-human fibrinogen [1:7000]; overnight, 4°C) 
before incubation with fluorescently-labeled secondary antibodies (1 hour, room temperature). 
Blots were visualized using a Typhoon FLA9000 Imager. Densitometry was performed with 
ImageJ 1.48v. FXIII activation was determined by dividing the intensity of the FXIII-Aʹ band by 
the sum of the FXIII-A and FXIII-Aʹ bands to obtain % of FXIII-Aʹ. Crosslinking of fibrin γ-
chains was determined as previously described.12,21 
 
Statistics. Descriptive statistics (mean, standard deviation [SD], standard error of the mean 
[SE]) were calculated and Lilliefors test was used to assess normality. FXIII-A2 and FXIII-B2 co-
precipitation with each fibrinogen variant was compared to γA/γA using ANOVA with Dunnett’s 
post-hoc testing (Kaleidagraph, Synergy Software, v4.5). FXIII activation and fibrin crosslinking 
rates were compared using 2-tailed Student’s t-tests for equal or unequal variances, as 
appropriate. P<0.05 was considered statistically significant.  
3.4 Results 
	  
Fibrinogen residues γ390-396 mediate FXIII-A2B2 binding to soluble human fibrinogen. 
Previous studies have suggested FXIII-A2B2 binds to fibrinogen at the alternatively-spliced γʹ-
chain8,9, residues in the αC domain11, or residues in the γ-chain4,12. To compare FXIII-A2B2 
binding to these regions of fibrinogen, we expressed and purified recombinant human fibrinogen 
proteins: wild-type (γA/γA), alternatively-spliced (γʹ/γʹ), αC-truncated (Aα251), and Fibγ390-396A. 
As expected14-16,22, each of these fibrinogen variants contained all three chains, polymerized 
normally, and were >95% clottable (Figure 3.1 and data not shown). We pre-incubated these  
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Figure 3.1. Fibrinogen residues γ390-396 are necessary for FXIII-A2B2 binding. 
Recombinant human fibrinogen variants (γA/γA, γʹ/γʹ, Aα251, and Fibγ390-396A) were mixed with 
FXIII-A2B2 (1 mg/mL [2.9 µM] and 20 µg/mL [60 nM], final, respectively) and precipitated with 
glycine. (A) Representative Western blots for fibrinogen (Fgn), FXIII-A, and FXIII-B in the 
initial sample (I), pellet (P), or supernatant (S). Note that P and S samples were prepared after the 
addition of glycine and are therefore diluted relative to the I sample. (B) Quantitation of all blots, 
indicating percent of FXIII-A or FXIII-B in the pellet, relative to total FXIII in the pellet and 
supernatant. Bars are means ± SE, N=3. 
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fibrinogen variants with FXIII-A2B2, precipitated fibrinogen with glycine, and performed SDS-
PAGE and Western blotting to identify FXIII-A2B2 present in the pellets and supernatant. FXIII-
A2B2 co-precipitated with γA/γA, γʹ/γʹ, and Aα251 fibrinogen constructs (Figure 3.1). However, 
co-precipitation of FXIII-A2B2 with Fibγ390-396A was reduced by 75% (P<0.0001, Figure 3.1).  
 We also quantified binding of the fibrinogen variants to FXIII-A2B2 using SPR. Consistent 
with the co-precipitation data, γA/γA and γʹ/γʹ fibrinogens bound FXIII-A2B2 with similar, high 
affinity (Table 3.1, Supplemental Figure 3.1). Compared to γA/γA and γʹ/γʹ fibrinogens, Aα251 
fibrinogen binding to adherent FXIII-A2B2 was slightly reduced, consistent with the finding that 
the αC domain contributes to FXIII-A2B2-binding function11. Regardless, given these affinity 
constants (Table 3.1), greater than 99% of circulating FXIII-A2B2 (plasma concentration ~43-86 
nM2,3) would bind each of these variants. In contrast, Fibγ390-396A fibrinogen did not bind FXIII-
A2B2 (Table 3.1, Supplemental Figure 3.1). Collectively, these data indicate the primary binding 
site for zymogen FXIII-A2B2 is present in γA/γA, γʹ/γʹ, and Aα251 fibrinogens, but absent in 
Fibγ390-396A fibrinogen. Together with previous findings4, these results suggest the highly-
conserved fibrinogen residues γ390-396 mediate binding of zymogen FXIII-A2B2 to fibrinogen 
in both mice and humans. 
 
 Human fibrin(ogen) residues γ390-396 mediate the ability of fibrin to accelerate FXIII-
A2B2 activation. During fibrin formation, FXIII-A2B2 binding to the fibrin D:E:D/thrombin 
complex accelerates FXIII activation peptide cleavage and FXIII activation.12,23-29 Using mice 
expressing murine Fibγ390-396A fibrinogen, we previously detected delayed FXIII activation and 
fibrin crosslinking in plasma.4 To directly determine the contribution of fibrin(ogen) residues 










Equilibrium dissociation constant 
(KD), nM 
FXIII-A2B2 γA/γA 6 3.8  ± 2.4 
 γʹ/γʹ 6 10.4  ± 11.1 
  Aα251 3 71.0  ± 16.2 
  Fibγ390-396A 6 No Binding 
     
rFXIII-B2 γA/γA 4 0.4  ± 0.3 
 γʹ/γʹ 6 53.0  ± 75.1 
  Aα251 4 58.6  ± 26.5 
  Fibγ390-396A 6 No Binding 
  
Table 3.1. SPR analysis of fibrinogen variant binding to immobilized FXIII-A2B2 and 
rFXIII-B2. Equilibrium dissociation constant values are mean ± SD for the number of 
experiments indicated (N).  
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Figure 3.2. Fibrin(ogen) residues γ390-396 mediate the acceleratory effect of fibrin(ogen) 
on FXIII-A2B2 activation. FXIII-A2B2 (20 µg/mL [60 nM], final) was mixed with recombinant 
fibrinogens (γA/γA or Fibγ390-396A, 150 µg/mL [440 nM], final) or buffer (No Fgn). Reactions 
were triggered by addition of thrombin (2 nM, final) and CaCl2 (10 mM, final), quenched at the 
indicated time points, and analyzed by SDS-PAGE with Western blotting and densitometry. 
Activation peptide cleavage was detected using anti-FXIII-A antibody. Fibrin crosslinking was 
detected using anti-fibrinogen antibody. (A) Representative Western blots and (B) quantitation of 
FXIII-A2B2 activation over time from all blots. (C) Maximal rates of FXIII-A2B2 activation 
calculated from panel B. (D) Representative Western blots of fibrin crosslinking, and 
quantitation of (E) γ-γ dimer formation and (F) γ-γ dimer formation rate. Data are means ± SE, 
N=3-6 replicates per time point. 
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support FXIII-A2B2 activation in a purified system. Compared to reactions with human γA/γA 
fibrin(ogen), reactions with Fibγ390-396A fibrin(ogen) showed 2.7-fold slower release of the FXIII 
activation peptide (2.35±0.46% versus 0.87±0.20% FXIII-Aʹ/minute, respectively, P<0.02, 
Figure 3.2A-C), and was similar to that observed in the absence of fibrinogen (0.96±0.16% 
FXIII-Aʹ/minute, P=0.8, Figure 3.2A-C).  
 The rate of fibrin formation was similar for γA/γA and Fibγ390-396A (Figure 3.2D and data not 
shown). However, the rate of fibrin crosslinking was slower for Fibγ390-396A. Specifically, γ-γ 
dimer formation was 2.5-fold slower (6.7±1.5 versus 17.0±1.3% γ-γ/minute, for Fibγ390-396A 
versus γA/γA, respectively, Figure 3.2D-F). The delays in both FXIII-A2B2 activation and 
crosslinking activity are consistent with a lack of binding of zymogen FXIII-A2B2 to Fibγ390-396A 
fibrinogen. 
 
 The ability of fibrin(ogen) residues γ390-396 to accelerate FXIII activation is FXIII-B 
subunit-dependent. Souri et al. previously suggested the acceleratory effect of fibrin(ogen) on 
FXIII-A2B2 activation is FXIII-B subunit-dependent.12 We therefore also measured activation of 
FXIII-A2 (rFXIII-A2) in the absence of FXIII-B2 and compared these rates in the presence of 
γA/γA and Fibγ390-396A fibrin(ogen). Compared to activation of FXIII-A2B2, activation of rFXIII-
A2 was slower (Figure 3.2A-C and Figure 3.3A-C, P<0.02), consistent with a critical role for the 
FXIII-B subunits in this reaction. Interestingly, however, in contrast to that seen with FXIII-
A2B2, activation of rFXIII-A2 was similar in the presence of γA/γA and Fibγ390-396A fibrin(ogen) 
(0.60±0.06 versus 0.46±0.06% FXIII-Aʹ/minute, respectively, Figure 3.3A-C). Moreover, in the 
presence of rFXIII-A2, the formation rate of γ-γ dimers was more similar for γA/γA and Fibγ390-
396A (15.6±0.5 versus 12.6±0.5% γ-γ/minute, respectively, Figure 3.3D-F), relative to reactions in  
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Figure 3.3. Fibrin(ogen) residues γ390-396 do not accelerate FXIII-A2 activation. 
Recombinant FXIII-A2 (10 µg/mL [60 nM], final) was mixed with γA/γA or Fibγ390-396A 
fibrinogen (150 µg/mL [440 nM], final). Reactions were triggered by addition of thrombin (2 
nM, final) and CaCl2 (10 mM, final), quenched at the indicated time points, and analyzed by 
SDS-PAGE with Western blotting and densitometry. Activation peptide cleavage was detected 
using anti-FXIII-A antibody. Fibrin crosslinking was detected using anti-fibrinogen antibody. 
(A) Representative Western blots and (B) quantitation of rFXIII-A2 activation over time from all 
blots. (C) Maximal rates of rFXIII-A2 activation were calculated from quantified Western blots. 
(D) Representative Western blots of fibrin crosslinking and quantification of (E) γ-γ dimer 





the presence of FXIII-A2B2. These findings show Fibγ390-396A can be crosslinked, indicating the  
delayed crosslinking seen with FXIII-A2B2 (Figure 3.2D-F) was not due to a substantial 
disruption of structure in this region. Rather, these data attribute the delay seen with FXIII-A2B2 
(Figure 3.2D-F) to decreased interaction between fibrin(ogen) residues γ390-396 and the FXIII-
B subunit. Together, these data suggest fibrin(ogen) residues γ390-396 accelerate FXIII 
activation, and do so in a FXIII-B subunit-dependent mechanism. 
 
 The FXIII-B subunit binds fibrinogen residues γ390-396. We then directly tested the 
hypothesis that FXIII binding to fibrinogen residues γ390-396 is mediated by the B subunits 
using both precipitation and SPR assays. First, we precipitated recombinant γA/γA or Fibγ390-396A 
fibrinogen in the presence of rFXIII-A2, rFXIII-B2, or rFXIII-A2 plus rFXIII-B2. rFXIII-A2 did 
not co-precipitate with either γA/γA or Fibγ390-396A fibrinogen (Figure 3.4A, B). However, 
rFXIII-B2 readily co-precipitated with γA/γA fibrinogen (Figure 3.4A), but not Fibγ390-396A 
fibrinogen (Figure 3.4B). Addition of rFXIII-B2 to rFXIII-A2 rescued co-precipitation of rFXIII-
A2 with γA/γA fibrinogen (Figure 3.4A), likely through the formation of rFXIII-A2B2 
heterotetramers. Conversely, rFXIII-B2 did not rescue rFXIII-A2 co-precipitation with Fibγ390-
396A (Figure 3.4B). Experiments using purified, plasma-derived γA/γA (peak 1) fibrinogen fully 
recapitulated findings with recombinant γA/γA (data not shown). 
 Second, we examined binding of the fibrinogen variants to surface-bound rFXIII-B2. These 
data revealed that γA/γA bound rFXIII-B2 with similar affinity as seen with FXIII-A2B2 (Table 
3.1, Supplemental Figure 3.2). γʹ/γʹ and Aα251 fibrinogens also bound rFXIII-B2 (Table 3.1, 
Supplemental Figure 3.2), indicating both that the binding motif for FXIII-B2 is present on each 







Figure 3.4. FXIII-A2B2 binds fibrinogen residues γ390-396 via the FXIII-B subunits. 
Recombinant FXIII-A2 (10 µg/mL [60 nM], final), rFXIII-B2 (10 µg/mL [62 nM], final), or 
both, were mixed with (A) γA/γA or (B) Fibγ390-396A fibrinogen (1 mg/mL [2.9 µM], final) 
and precipitated with glycine. (A-B) Representative Western blots for fibrinogen (Fgn), FXIII-A, 
and FXIII-B in the initial sample (I), pellet (P), or supernatant (S). Note that P and S samples 
were prepared after the addition of glycine and are therefore diluted relative to the I sample. 
Blots are representative of N=3 experiments. 
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binding to fibrinogen. These data also confirm that rFXIII-B2 co-precipitation with fibrinogen in 
the previous experiments was not due to the presence of glycine. Notably, however, we were 
unable to detect binding of Fibγ390-396A fibrinogen to rFXIII-B2 (Table 3.1, Supplemental Figure 
3.2). Collectively, these co-precipitation and SPR data indicate that the FXIII-B subunit(s) of 
FXIII-A2B2 mediate binding to fibrinogen residues γ390-396. 
 
 Excess FXIII-B2 in plasma circulates bound to fibrinogen. FXIII-B2 is present in ~2-fold 
molar excess over FXIII-A2 in plasma and is reported to circulate as free (unbound) FXIII-B2 
homodimer.2,3 However, the co-precipitation and SPR data indicating FXIII-B2 can bind 
fibrinogen in the absence of FXIII-A2 (Figure 3.4A, Table 3.1) raise the interesting possibility 
that “free” FXIII-B2 in plasma actually circulates bound to fibrinogen. Indeed, given the 
measured affinity of FXIII-B2 to fibrinogen (0.4 nM, Table 3.1) and the estimated plasma 
concentration of “free” FXIII-B2 (~43-62 nM)2,3, greater than 99% of circulating FXIII-B2 
should be bound to fibrinogen. Therefore, to determine whether FXIII-B2 circulates with 
fibrinogen in plasma, we precipitated fibrinogen from plasma from FXIII-A2-sufficient (F13a+/+) 
and FXIII-A2-deficient (F13a+/- and F13a-/-) mice4,17 and used SDS-PAGE and Western blotting 
to detect FXIII-B in the precipitate. Consistent with previous observations30, there was a FXIII-A 
subunit dose effect on the total amount of FXIII-B present in the initial plasma sample (Figure 
3.5A), suggesting FXIII-A2 influences the circulating level of FXIII-B2. Regardless, Figure 3.5A 
shows that FXIII-B2 co-precipitated with fibrinogen from FXIII-A-deficient plasma. 
Experiments using FXIII-A-deficient human plasma fully recapitulated findings with FXIII-A-
deficient mouse plasma (Figure 3.5B). To test the specificity of the precipitation protocol, we 
subjected afibrinogenemic mouse plasma to glycine precipitation. As expected, no fibrinogen  
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Figure 3.5. In the absence of FXIII-A2, FXIII-B2 co-precipitates with plasma fibrinogen. 
Fibrinogen was precipitated from (A) F13a+/+, F13a+/-, or F13a-/- mouse plasma, (B) FXIII-
depleted human plasma, or (C) afibrinogenemic mouse plasma using glycine. Panels show 
representative Western blots for fibrinogen (Fgn), FXIII-A, and FXIII-B in the initial plasma (I), 
pellet (P), or supernatant (S) under reducing (Fgn) or non-reducing (FXIII-A, FXIII-B) 
conditions. Note in panel A, plasma albumin in I and S samples causes the Aα-chain to migrate 
faster than in the P samples. Blots are representative of N=3 experiments with mouse plasmas, 
and N=2 experiments with human plasma. 
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was precipitated (Figure 3.5C). Importantly, glycine did not precipitate FXIII-B2 from 
afibrinogenemic mouse plasma (Figure 3.5C), indicating that FXIII precipitation in these 
experiments is fibrinogen-dependent. Thus, these data suggest excess FXIII-B2 in plasma does 
not circulate in a “free” state, but instead circulates bound to fibrinogen. 
3.5 Discussion 
	  
 The observation that FXIII-A2B2 circulates in complex with fibrinogen is well-established; 
however, the motifs on fibrinogen and FXIII-A2B2 that mediate this interaction have been 
controversial. Our study that integrates both solid- and solution-phase binding experiments and 
functional assays reveals critical components of both fibrinogen and FXIII-A2B2 necessary for 
binding. First, our data indicate that the primary binding site for zymogen FXIII-A2B2 on human 
fibrinogen is not found in the alternatively-spliced γʹ-extension or the αC region, but instead lies 
within γ-chain residues 390-396. Together with data from mice4, this finding suggests these 
highly-conserved fibrinogen residues mediate this interaction in multiple species. Second, we 
showed that FXIII-A2B2 binds fibrinogen residues γ390-396 via the FXIII-B subunits. These data 
support previous studies suggesting an interaction between the FXIII-B subunit and 
fibrinogen8,12, and extend these findings by defining the FXIII-B binding motif on fibrinogen. 
Third, we showed that FXIII-B2 can bind fibrinogen in the absence of FXIII-A2. This intriguing 
finding suggests “free” FXIII-B2 in plasma actually circulates bound to fibrinogen, and has 
important implications for understanding assembly of the fibrinogen/FXIII-A2B2 complex in 
both physiologic and therapeutic situations.  
 Our finding that fibrinogen residues γ390-396 support FXIII-A2B2 binding is consistent with 
several prior studies implicating the D-domain31, residues C-terminal to residue Lys356 of the γ-
chain12, and residues γ390-396 of murine fibrinogen4 in this interaction. However, our findings 
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are discordant with studies implicating the alternatively-spliced γʹ-chain8,9 as the primary 
mediator of this interaction. The reasons for this discord may relate to differences in the assay 
systems used. For example, although experiments using anion exchange chromatography 
suggested FXIII-A2B2 elutes in the same fraction as γA/γʹ, this study did not directly compare 
binding of FXIII-A2B2 to these fibrinogen variants.8 In contrast we tested this interaction by both 
co-precipitation and direct binding assays that enabled us to maintain fibrinogen in solution 
during the binding events. This assay design may be particularly important because the same 
residues we have implicated in FXIII-A2B2 binding have previously been shown to support 
fibrin(ogen) binding to the CD11b (αM) subunit of CD11b/CD18 (Mac-1) integrin present on 
monocytes, macrophages, and neutrophils.22,32 The observation from those studies that CD11b 
binds to residues γ390-396 in insoluble fibrin and adherent fibrin(ogen), but not soluble 
fibrinogen, has led to the hypothesis that fibrin formation or fibrinogen adherence to a surface 
induces structural changes within these residues. Thus, previous experimental designs that used 
surface (or resin)-bound fibrin(ogen) or fibrin6,8,27,33,34 may not have recapitulated the 
conformation of residues γ390-396 that would bind zymogen FXIII when fibrinogen is in 
solution. This possibility is also interesting when considering the role of the nearby fibrin(ogen) 
γʹ extension (residues 407-427) in FXIII-A2B2 binding. If residues in the γʹ-extension influence 
structure within residues γ390-396, data from assays using surface- or resin-bound fibrin(ogen) 
or fibrin may have indicated the alternatively-spliced γʹ-chain has different affinity for FXIII-
A2B2. Similarly, ultracentrifugation experiments with γA/γʹ fibrinogen9 may have been 
confounded by the presence of gel-like fibrin(ogen) dimers35,36. Thus, these conditions may have 
led to the conclusion that the zymogen binding motif is contained within the γʹ-extension. 
 More recent findings that FXIII-A2B2 binds to a peptide derived from the fibrinogen αC 
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domain (residues α371-425) suggested FXIII-A2B2 binds to the fibrinogen αC region.11 In that 
study11 it was not possible to distinguish the relative contributions of the αC region versus the D-
region to this interaction in full-length fibrinogen. Our SPR data indicating Aα251 fibrinogen has 
weaker binding than γA/γA fibrinogen to FXIII-A2B2 suggest some FXIII-binding character is 
derived from the αC domain. Future studies using variant fibrinogens with combined mutations 
in the γ- and α-chains may resolve the relative contribution of the αC region in this interaction.  
 The high degree of inter-species homology within fibrinogen residues γ390-396 has 
traditionally been attributed to their other essential function in supporting fibrin(ogen) binding to 
CD11b.22,32 Interestingly, the earliest FXIII-fibrinogen system37 and the αM I-domain that binds 
fibrin38,39 appeared together with the rise of vertebrates over 400 million years ago. No 
homozygous mutations have been identified in this region, emphasizing the physiologic 
importance of this fibrin(ogen) sequence. Therefore, the high homology in this region may result 
from strong evolutionary pressure to maintain both of these functions. Although the same 
fibrinogen residues mediate binding to both FXIII-A2B2 and CD11b, it is unlikely that these 
binding events compete. First, there is a vast excess of fibrinogen relative to FXIII-A2B2. 
Second, FXIII-A2B2 circulates with soluble fibrinogen6, whereas CD11b binds insoluble fibrin40. 
Thus, these interactions likely occur in distinct physiologic settings. 
 Based on our and published findings, we propose the following model (Figure 3.6). FXIII-
A2B2 circulates bound to fibrinogen at a site comprised of residues γ390-396 and supported by 
the αC region.11 During coagulation, fibrinogen transports FXIII-A2B2 into the nascent clot via 
its interaction with the FXIII-B subunits. As fibrin polymerizes, FXIII-A2B2 bound to the D-
domain of one fibrin monomer contacts thrombin bound to the E-domain of another fibrin 
monomer at the D:E:D interface.41 Formation of this complex promotes FXIII activation peptide  
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Figure 3.6. FXIII-A2B2 binding to fibrinogen residues γ390-396 promotes FXIII-A2B2 
activation and activity. (A) Fibrinogen is comprised of two Aα- (medium gray), two Bβ- (dark 
gray), and two γ-chains (light gray) arranged in a trinodular structure with two distal D-domains 
and a central E-domain. The Aα-chains have a C-terminal domain (αC) that extends beyond the 
D-domain. FXIII-A2B2 circulates bound to fibrinogen γ-chain residues 390-396 via the FXIII-B 
subunits. (B) Once coagulation is initiated, thrombin interacts with the fibrinogen E-domain and 
cleaves fibrinopeptides A from the Aα-chains. As fibrin monomers polymerize, FXIII-A2B2 
associated with γ390-396 is brought into contact with thrombin at the D:E:D interface to form a 
ternary complex.41 This complex facilitates thrombin-mediated activation peptide cleavage from 
the FXIII-A subunits.23-29,41 (C) Following activation peptide cleavage, fibrin promotes the 
calcium-mediated FXIII-B subunit dissociation from the FXIII-A subunits to yield FXIIIa (active 
sites indicated by stars).12,23 FXIIIa then crosslinks (black line) the nearby γ-chains yielding γ-γ 
dimers.21  This γ-chain crosslinking also promotes dissociation of FXIII-B2 from the fibrin clot.12 
(D) FXIIIa translocates from the γ-chain to the αC region, binding at or near α-chain residue 
E39611,45,46, and catalyzes the formation of crosslinks between fibrin α-chains and between fibrin 
and other plasma proteins. 
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cleavage and release from the FXIII-A subunits23-29,41, followed by dissociation of the FXIII-B 
subunits from the FXIII-A subunits12,23. These sequential steps yield fully-activated FXIII-A2*. 
Generation of FXIII-A2* at residues γ390-396 conveniently localizes FXIIIa near the γ-chain 
crosslinking sites (residues γQ398/399 and γK406), which are the first fibrin residues to undergo 
crosslinking.21,42-44 This γ-chain crosslinking also promotes FXIII-B2 dissociation from the fibrin 
clot.12 The FXIII-A2* interaction with αC residue E39611,45,46 then facilitates the translocation of 
its active site to the fibrin α-chain, where it catalyzes the formation of crosslinks between fibrin 
α-chains and between α-chains and other plasma proteins. Formation of these crosslinks is 
critical for the ability of FXIII(a) to promote resistance of clots to biomechanical and 
biochemical disruption. Moreover, we recently showed that the spatio-temporal regulation of 
FXIII activation kinetics during coagulation is also critical for determining red blood cell 
retention in contracted clots.4 Thus, this model reconciles data from studies on the binding, 
activation, and activity of FXIII and reveals the importance of the FXIII-B subunits in 
fibrinogen/FXIII-A2B2 interactions, in FXIII-A2B2 activation, and consequently, in fibrin 
crosslinking and clot composition and stability. Although we did not identify the specific FXIII-
B residues that mediate this interaction, previous studies have implicated sushi domains 1 and/or 
10 in this interaction.12 Further studies are ongoing to localize the FXIII-B residues that support 
binding to fibrinogen residues γ390-396. 
 A major finding from this work is the observation that FXIII-B2 can bind fibrinogen in the 
absence of FXIII-A2. Notably, the tight affinity of FXIII-B2 binding to fibrinogen, together with 
the plasma concentrations of FXIII-B2 and fibrinogen, suggests essentially all FXIII-B2 in 
plasma is bound to fibrinogen. This observation appears to contradict the tenet that “free B” 
circulates in plasma.3 However, FXIII-B2 used in the previous report3 was prepared by 
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ammonium sulfate precipitation and heat denaturation to specifically remove fibrinogen. Thus, 
that study was not designed to characterize FXIII binding to other plasma proteins, and “free B” 
was likely only meant to imply “not bound to FXIII-A2.” This nomenclature has been interpreted 
overly-broadly since that time. Since both FXIII-B2 and fibrinogen are synthesized by 
hepatocytes, these proteins may associate during or immediately following their secretion. 
Subsequent association of the FXIII-A2 subunits, which are synthesized by cells of bone marrow 
origin, with the fibrinogen/FXIII-B2 complex would then result in formation of the complete 
fibrinogen/FXIII-A2B2 complex. Consequently, our data that suggest FXIII-B2 circulates bound 
to fibrinogen may reveal part of a step-wise mechanism that leads to production of 
fibrinogen/FXIII-A2B2 complexes. In addition, these data may have important implications for 
understanding the mechanism of action of therapeutic rFXIII-A2 infusion for FXIII-A-
deficiency. Binding of infused rFXIII-A2 to fibrinogen-bound FXIII-B2 (versus “free” FXIII-B2) 
ensures that rFXIII-A2 becomes incorporated into a functional, fibrinogen-bound complex that is 
crucial for normal FXIII activation and function. 
 Our study has potential limitations. First, loss of FXIII binding to Fibγ390-396A may reflect 
disrupted structure within the γ-domain. However, this possibility seems unlikely because 
crystallographic studies suggest this region is disordered even in the native molecule.47-49 
Moreover, although the pattern of fibrin crosslinking is subtly altered in both mouse4 and human 
Fibγ390-396A clots, both murine4,22 and human Fibγ390-396A can be fully crosslinked at the canonical 
residues located immediately C-terminal to γ390-396 (γQ398/399 and γK406). Thus, mutations 
within these residues do not appear to catastrophically alter structure within this domain. Second, 
the protocol used to precipitate fibrinogen may also promote FXIII precipitation and/or FXIII 
interaction with fibrinogen, and we and others8 have observed spontaneous precipitation of 
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isolated FXIII-B subunits in certain experiments. However, glycine did not precipitate FXIII 
from afibrinogenemic plasma or in the presence of non-binding Fibγ390-396A fibrinogen. 
Moreover, data from the precipitation experiments were supported by both SPR analyses and 
functional FXIII activation assays performed in the absence of glycine.  
 In summary, our data expose critical molecular interactions mediating FXIII binding to 
fibrinogen. Identification of these motifs advances our understanding of this interaction in both 
physiologic and pathophysiologic situations. 




Supplemental Figure 3.1. Recombinant fibrinogen binding to FXIII-A2B2. Surface plasmon 
resonance (SPR) was performed using OneStep® titration as described in the Methods and 
Supplemental Methods. Representative SPR binding curves using 1 µM fibrinogen (maximum) 
for (A) γA/γA, (B) γʹ/γʹ, (C) Aα251, and (D) Fibγ390-396 binding to FXIII-A2B2. Curves 




Supplemental Figure 3.2. Recombinant fibrinogen binding to FXIII-B2. SPR was performed 
as described in the Methods and Supplemental Methods. Representative SPR binding curves 
using 1 µM fibrinogen (maximum) for (A) γA/γA, (B) γʹ/γʹ, (C) Aα251, and (D) Fibγ390-396A 
binding to recombinant FXIII-B2. Curves representative of N=4-6 experiments as indicated in 
Table 3.1. 
A B C D 
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CHAPTER 4: RECIPROCAL, INTER-TISSUE REGULATION OF FACTOR XIII-A 
AND -B SUBUNITS DETERMINES FACTOR XIII LEVELS IN PLASMA 
 
4.1 Overview 
Plasma coagulation factor XIII (FXIII) is composed of two FXIII-A and two FXIII-B 
subunits (FXIII-A2B2). Bone marrow-derived cells produce FXIII-A, whereas F13b mRNA is 
found in the liver and kidney. Interestingly, FXIII-A-deficient mice and humans have decreased 
FXIII-B. In humans, therapeutic infusion of recombinant FXIII-A2 (rFXIII-A2) increases FXIII-
B. The mechanism mediating this inter-tissue reciprocal regulation has not been defined. To 
examine this relationship, we developed a mouse model of rFXIII-A2 infusion. Infused F13a-/- 
mice showed 8-fold increased FXIII-B 30 hours post-infusion. FXIII-B clearance was slightly 
reduced when complexed with FXIII-A, suggesting FXIII-A contributes to FXIII-B stability. 
However, the pharmacokinetic profile of FXIII-B after rFXIII-A2 infusion also indicated de novo 
FXIII-B production. FXIII-B was not released from intracellular stores, and rFXIII-A2 infusion 
did not elevate liver or kidney F13b mRNA relative to untreated controls. Proteomic profiling of 
liver lysates from F13a+/+, F13a-/-, and rFXIII-A2-infused F13a-/- mice revealed significant 
enrichment of RNA-binding proteins in both F13a+/+ and rFXIII-A2-infused F13a-/- mice relative 
to F13a-/- mice. In contrast, proteomic profiling of kidney tissue revealed evidence of cell stress 
in rFXIII-A2-infused mice, but no increase in RNA-binding proteins. These data suggest a liver-
specific effect of FXIII-A. Accordingly, rFXIII-A2 treatment increased FXIII-B production in 
two human hepatocellular carcinoma lines. In conclusion, FXIII-B promotes FXIII-A stability, 
while FXIII-A increases FXIII-B stability and production. FXIII-A specifically increased liver 
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RNA-binding proteins, which may post-transcriptionally regulate F13b. Identification of this 
unique regulatory mechanism exposes inter-tissue crosstalk critical for hemostasis and identifies 
a newly-recognized function of FXIII-A in modulating liver function. 
4.2 Introduction 
	  
Plasma coagulation Factor XIII (FXIII) is a protransglutaminase composed of two A (FXIII-
A) and two B (FXIII-B) subunits arranged as a non-covalent heterotetramer (FXIII-A2B2). FXIII-
A and -B arise from distinct tissues. FXIII-A polymorphisms track with bone marrow 
transplantation in humans, indicating cells of bone marrow origin are the source of plasma 
FXIII-A.1 Recent murine Cre/lox studies revealed tissue resident macrophages produce plasma 
FXIII-A.2 Hepatoma cell lines synthesize FXIII-B in vitro3 and FXIII-B polymorphisms track 
with human liver transplantation, suggesting that the liver is the site of FXIII-B synthesis.1 
However, F13b mRNA is found in both the mouse liver and kidney4. FXIII-A2B2 assembly 
occurs in plasma, and essentially all plasma FXIII-A circulates tightly bound to FXIII-B. There 
is also an excess of uncomplexed FXIII-B in circulation (43-62 nM).5  
Relative to FXIII-A2B2, FXIII-A has a short plasma half-life (t1/2 ~9-10 days and <10 hours, 
respectively)6,7, indicating FXIII-B stabilizes FXIII-A. Interestingly, several lines of evidence 
suggest FXIII-A regulates FXIII-B. First, there is a F13A gene-dose-dependent effect on plasma 
FXIII-B levels: FXIII-A-deficient individuals exhibit over 2-fold reduced FXIII-B.8 Similarly, 
F13a-/- mice exhibit a ~5-fold reduction in FXIII-B.4,9 Second, recombinant FXIII-A2 (rFXIII-
A2) infusion in both monkeys10 and humans7 increases plasma FXIII-B. FXIII-B continues to rise 
even after FXIII-A2B2 begins to fall. The mechanism underlying this unique, inter-tissue, 
reciprocal regulation is unclear. Instances of reciprocal protein regulation are common in 
intracellular feedback loops11, and natural killer and autoreactive T cell populations exhibit 
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systemic, cellular reciprocal regulation12. However, an inter-tissue, reciprocal regulatory 
mechanism where two protein subunits regulate their respective levels systemically has, to our 
knowledge, not previously been described. 
Herein, we use in vitro, in vivo, and proteomics approaches to define the mechanism of 
FXIII-A-mediated FXIII-B regulation. Our findings demonstrate that FXIII-A upregulates RNA-
binding proteins in the murine liver, which may be involved in post-transcriptional regulation of 
F13b and other mRNA transcripts. These findings are the first to implicate FXIII-A as a 
regulator of liver function.  
4.3 Methods 
Materials and Proteins. Recombinant human FXIII-A2 (rFXIII-A2) was a gift of Novo 
Nordisk (Bagsvaerd, Denmark). Anti-human FXIII-A antibody (SAF13A-AP) and human 
thrombin was from Enzyme Research Laboratories (South Bend, IN). T101, recombinant FXIII-
B2 (rFXIII-B2), and anti-human FXIII-B antibody (A074) were from Zedira (Darmstadt, 
Germany). Anti-human fibrinogen antibody (A0080) was from Dako (Carpinteria, CA). Plasma-
derived FXIII-A2B2 was a gift of CSL-Behring (King of Prussia, PA). Recombinant hirudin was 
from Hyphen Biomed (Neuville-sur-Oise, France). Cell culture media and supplements were 
from Gibco (Montgomery County, MD). Fetal bovine serum (FBS) was from Sigma (St. Louis, 
MO). 
 
Western blot determination of plasma fibrinogen, FXIII-A and -B levels. The University 
of North Carolina at Chapel Hill Institution of Animal Care and Use Committee approved all 
murine studies. Murine blood was harvested from the inferior vena cava (IVC) into 3.2% sodium 
citrate (10% vol/vol) and processed to platelet-poor plasma (PPP) by centrifugation (5000g, 10 
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minutes). PPP was diluted 1:6 (FXIII-B blots) or 1:120 (fibrinogen, FXIII-A blots) in water and 
6X sodium dodecyl sulfate (SDS) loading buffer (Boston Bioproducts, Ashland, MA) before 
boiling under nonreducing (FXIII-B) or reducing (2.5% β-mercaptoethanol, fibrinogen, FXIII-A) 
conditions. Samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 
10% Tris-Glycine gels (Bio-Rad, Hercules, CA) before transfer to polyvinylidene fluoride 
membranes (Millipore, Burlington, MA). Membranes were probed with primary antibodies 
(rabbit anti-fibrinogen [1:7000, 4°C overnight], sheep anti-FXIII-A [1:1000, 4°C overnight] or 
rabbit anti-FXIII-B [1:500, room temperature overnight]). Blots were visualized using the 
appropriate fluorescent secondary antibody (1:10000, 1 hour, room temperature) and a GE 
Typhoon FLA9000 Imager (GE Healthcare, Little Chalfont, United Kingdom). Densitometry 
was performed using ImageJ 1.48v and a standard sample was used to normalize between blots.  
 
rFXIII-A2 infusions. 8-12 week old FXIII-A-deficient (F13a-/-)13 mice were anesthetized 
using 3% isoflurane in oxygen. rFXIII-A2 (0.875 mg/mL in sterile saline) was infused via the tail 
vein using a 30G sterile needle and syringe. Mice received 4 mg/kg rFXIII-A2 as previously 
described.14 Blood was harvested over time from the retro-orbital sinus or the IVC into 3.2% 
sodium citrate (10% vol/vol, final). Blood for the 0 hour timepoint was collected immediately 
post-infusion. At the end of the time course, mice were sacrificed. Organs were harvested and 
flash frozen for subsequent analysis. Isolated blood was processed to PPP as described above and 
flash frozen. 
 
In vivo FXIII-B clearance. FXIII-A2B2 (0.5 mg/mL, final) was pre-activated in sterile N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid (HEPES)-buffered saline (HBS, 20 mM 
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HEPES, 150 mM NaCl, pH 7.4) using thrombin (10 nM, final) and calcium (CaCl2, 10 mM, 
final) to separate the FXIII-A and -B subunits. The reaction proceeded for 1 hour at 37°C in the 
presence of the FXIII inhibitor T101 (250 µM, final) to inhibit active FXIII-A subunits (FXIII-
A2*I). Reactions were quenched (30 minutes at 37°C) with a 6-fold molar excess of recombinant 
hirudin to inhibit thrombin. Unactivated FXIII-A2B2 was prepared by adding FXIII-A2B2 to 
reactions following thrombin inhibition. Pre-activated or unactivated FXIII-A2B2 was infused 
into F13a-/- mice as above, except the dose was reduced to 2 mg/kg. Plasma was harvested at the 
times indicated. 
 
Real-time quantitative reverse polymerase chain reaction (RT-qPCR) of F13b 
transcripts. Tissue from F13a+/+, F13a-/-, and rFXIII-A2-treated F13a-/- mice was harvested (48 
hours post-infusion for rFXIII-A2-treated mice) as above and immediately flash frozen. Tissue 
was cryogenically pulverized and RNA isolated from tissue powder using QiaShredder and 
RNeasy Mini Kits (Qiagen, Hilden, Germany) per the manufacturer’s instructions. RNA was 
quantified on a Spectramax Plus 384 microplate reader with a SpectraDrop micro volume plate 
(Molecular Devices, Sunnyvale, CA). 1 µg of RNA was converted to cDNA using the 
QuantiTect reverse transcription kit (Qiagen) and RT-qPCR was performed performed using the 
QuantiFast SYBR Green kit (Qiagen) with a 7500 Fast Real-Time PCR system (Applied 
Biosystems, Foster City, CA). F13b transcript levels (forward primer: 
CGCTGAGACACTTGCCATTTA, reverse: GTCTACGCTCATGGGGAAGTA) were 
compared using the ΔΔCT method, relative to F13a-/-. Gapdh was used as a housekeeping gene 
(forward primer: TGGCCTTCCGTGTTCCTAC, reverse: GAGTTGCTGTTGAAGTCGCA). 
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Sample preparation for LC-MS/MS analysis. Livers and kidneys from F13a+/+, F13a-/-, 
and rFXIII-A2-treated F13a-/- mice were harvested processed as above. At least three biological 
replicates were used for each condition. Tissue powder was lysed using tPer lysis buffer (Thermo 
Scientific, Rockford, IL) supplemented with protease inhibitors (Cell Signaling, Danvers, MA) 
and homogenized using a sterile 25G needle and syringe. Protein was quantified with 
bicinchoninic acid assay (Thermo) and total protein concentrations normalized to the same value. 
Samples were acetone precipitated by adding four times the sample volume with cold acetone 
overnight, followed by centrifugation at 16,000 RPM for 15 minutes. Each sample (50 µg) was 
reduced with 5 mM dithiothreitol for 30 minutes at 56ºC, and then alkylated with 15 mM 
iodoacetamide in the dark at room temperature. Samples were digested with trypsin (Promega, 
Madison, WI) overnight at 37ºC, and the peptide samples were desalted using C18 spin columns 
(Pierce, Rockford IL). Peptide samples were dried down via vacuum centrifugation and 
reconstituted in 5% acetonitrile/0.1% formic acid. Peptides were quantified using the Pierce 
Quantitative Colorimetric Peptide Assay. 
 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The peptide 
samples (1 µg) were analyzed by LC-MS/MS using an Easy nanoLC 1000 coupled to a 
QExactive HF mass spectrometer (Thermo). Samples were injected onto an Easy Spray PepMap 
C18 column (75 µm inner diameter × 25 cm, 2 µm particle size, Thermo) and separated using a 2 
hour method. The gradient for separation consisted of 5–32% mobile phase B at a 250 nL/min 
flow rate, where mobile phase A was 0.1% formic acid in water and mobile phase B consisted of 
0.1% formic acid in acetonitrile. The QExactive HF was operated in data-dependent mode where 
the 15 most intense precursors were selected for subsequent fragmentation. Resolution for the 
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precursor scan (m/z 400–1600) was set to 120,000 with a target value of 3×106 ions. MS/MS 
scan resolution was set to 15,000 with a target value of 5×104 ions. The normalized collision 
energy was set to 27% for higher-energy collisional dissociation. Peptide match was set to 
preferred, and precursors with unknown charge or a charge state of 1 and ≥ 7 were excluded. 
 
Data analysis. Raw data files were processed using MaxQuant version 1.5.3.17 and searched 
against a Uniprot mouse database (downloaded April 2017, containing 50,936 entries), using 
Andromeda within MaxQuant. Enzyme specificity was set to trypsin, up to two missed cleavage 
sites were allowed, carbamidomethylation of cysteine was set as a fixed modification and 
oxidation of Met was set as a variable modification. A 1% false discovery rate was used to filter 
all data. Label-free quantification using razor + unique peptides and match between runs (2 
minute time window) were enabled. Quantified protein data were analyzed using Perseus v1.51 
(Max Planc Institute of Biochemistry). Briefly, contaminants and reverse sequences were 
removed, as were proteins that were identified in less than 60% of the samples. Data were 
imputed from a normal distribution of protein intensities and missing values replaced. Over-
imputed samples and outliers by principal component analysis were removed. Data were then 
log2 transformed and converted into normalized Z-scores for ANOVA. Proteins with a 
significance of P<0.05 were used in subsequent hierarchical clustering in Perseus. Enrichment 
analysis was performed using the STRING database.15 Enrichments with a P<0.01 were 
considered significant. 
 
Cell culture models. HEK293 cells were cultured in Eagle’s minimum essential medium 
supplemented 1X penicillin/streptomycin and 10% FBS. HepG2 cells were cultured in Eagle’s 
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minimum essential medium supplemented with 1X non-essential amino acids, 1 mM sodium 
pyruvate, 1X penicillin/streptomycin, and 10% FBS. Huh7 cells were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% FBS and 1X antibiotic/antimycotic. For 
FXIII-B production studies, cells were maintained in serum-free media supplemented with 10 
µg/mL insulin-transferrin-selenite (Roche, Basel, Switzerland) and 10 U/mL bovine lung 
aprotinin (Calbiochem, San Diego, CA). Conditioned media from cells cultured in the presence 
of vehicle or rFXIII-A2 was collected after 3-5 days, concentrated 10-fold using 3,000 dalton 
molecular weight cutoff centrifugal concentrator columns (Millipore), and FXIII-B visualized by 
Western blot as above. For siRNA knockdown in Huh7 cells, cells were transfected with 100 nM 
siRNA using RNAiMAX Lipofectamine in OptiMEM media (Thermo) per the manufacturer’s 
protocol for reverse transfection. Cells were transfected with 100 nM SilencerSelect Negative 
Control #1, SilencerSelect Gapdh Positive Control, or F13b siRNA (s4958, Thermo). 24 hours 
after transfection, cells were switched to serum-free media and media harvested after 3 days for 
FXIII-B analysis. Cell proliferation was measured with by MTT viability assay (Thermo). 
4.4 Results 
	  
FXIII-A increases FXIII-B in mice. Both FXIII-A-deficient humans8 and mice4 exhibit 
reduced levels of plasma FXIII-B. Relative to F13a+/+ mice, F13a+/- mice have ~60% reduced 
plasma FXIII-A and F13a-/- mice are completely FXIII-A-deficient.16 Compared to F13a+/+, 
F13a+/- and F13a-/- mice had 33% and 90% reduced levels of FXIII-B, respectively (Figure 
4.1A-B). FXIII-B levels in F13a-/- mice did not vary with gender or time of day (data not 
shown). FXIII-B binds both FXIII-A and fibrinogen in plasma9, so we first tested the role of  
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Figure 4.1. FXIII-A increases FXIII-B in vivo. (A) FXIII-A and -B in F13a+/+, F13a+/- or 
F13a-/- mouse plasma was visualized using Western blot with anti-FXIII-A or -B antibodies. 
Each lane represents plasma from one mouse. (B) FXIII-B band intensity was quantified using 
densitometry. Each dot represents one mouse and lines represent mean -/+ standard deviation 
(SD). (C) Fibrinogen, FXIII-A, and FXIII-B were visualized in plasma from wild-type (WT), 
Fibγ390-396A, or afibrinogenemic (Fgg-/-) mice with Western blot using anti-fibrinogen, anti-FXIII-
A, and anti-FXIII-B antibodies. (D) Schematic of in vivo rFXIII-A2 infusion model. 8-12 week 
old F13a-/- mice were infused with rFXIII-A2 (4 mg/kg) via the tail vein and blood was collected 
at various times post-infusion. (E) Plasma FXIII-A and -B levels at the indicated times post-
infusion were visualized by Western blot with anti-FXIII-A and FXIII-B antibodies, 
respectively. Representative blots are shown. (F) FXIII-A and -B were quantified using 
densitometry and compared to levels at the 0 hour timepoint. Dots represent means -/+ standard 
error (SE), N=3-18. 
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fibrinogen in mediating FXIII-B levels. Western blotting revealed normal FXIII-A and -B 
subunit levels in plasma from afibrinogenemic (Fgg-/-) mice and mice with disrupted FXIII-
fibrinogen binding (Fibγ390-396A)17 (Figure 4.1C). These data indicate that fibrinogen is not 
required to maintain FXIII in circulation, and suggest FXIII-A mediates plasma FXIII-B. 
To investigate the role of FXIII-A in modulating FXIII-B, we developed an in vivo model of 
FXIII-B production using F13a-/- mice. We infused F13a-/- mice with human rFXIII-A2 (4 
mg/kg, IV, Figure 4.1D) and measured plasma FXIII over time. FXIII-A exhibited biphasic 
clearance (Figure 4.1E-F). These two clearance phases likely represent initial, rapid clearance of 
uncomplexed FXIII-A and later, slow clearance of FXIII-A in complex with FXIII-B (FXIII-
A2B2). FXIII-B levels rose after a brief (~3 hour) lag-time, and maximal FXIII-B occurred 30 
hours post-infusion (7.8-fold increased, Figure 4.1E-F). After 30 hours, FXIII-B slowly 
decreased (Figure 4.1E-F). We observed similar trends in another line of FXIII-A-deficient mice 
(data not shown). These findings indicate FXIII-A regulates plasma FXIII-B in mice. 
 
FXIII-A reduces FXIII-B clearance. We first hypothesized that FXIII-A stabilizes FXIII-B 
in plasma. To evaluate FXIII-B clearance in vivo, we infused F13a-/- mice with FXIII-B in its 
FXIII-A-complexed (FXIII-A2B2) or -uncomplexed (FXIII-B2) form (Figure 4.2A). Western 
blotting of plasmas harvested post-infusion revealed both subunits were more rapidly cleared 
when uncomplexed (Figure 4.2B-C). To determine if FXIII-A protects FXIII-B from proteolytic 
degradation in the plasma compartment, we incubated rFXIII-B2 in human plasma for 24 hours at 
37°C in the absence or presence of rFXIII-A2. Western blotting showed that rFXIII-B2 did not 
degrade, even in the absence of rFXIII-A2 (Figure 4.2D). Together, these findings suggest that 
FXIII-A reduces FXIII-B clearance from plasma. 
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Figure 4.2. FXIII-A stabilizes FXIII-B in plasma. (A) Schematic of in vitro FXIII-A2B2 
activation with thrombin (10 nM) and CaCl2 (10 mM) to separate FXIII-A and -B subunits prior 
to infusion. Reactions were performed in the presence of the transglutaminase inhibitor T101 
(250 µM) and thrombin was inhibited with a 6-fold molar excess of hirudin prior to infusion in 
F13a-/- mice via the tail vein. (B) Representative Western blot of FXIII-A and -B levels in mice 
infused with complexed (FXIII-A2B2) or uncomplexed (FXIII-B + FXIII-A2*I) at the indicated 
times post-infusion using anti-FXIII-A and -B antibodies. (C) FXIII-A (blue) and -B (red) levels 
were quantified for each condition (solid line, complexed; dashed line, uncomplexed) using 
densitometry and compared to levels at the 0 hour timepoint. Data represent means -/+ SD, N=2-
9. (D) rFXIII-B2 was incubated in human plasma for 24 hours at 37°C in the absence or presence 
of rFXIII-A2 and visualized using Western blot with anti-FXIII-B antibody. Representative blot 







Figure 4.3. FXIII-A does not alter F13b transcription. F13b mRNA was quantified in liver 
(A) and kidney (B) tissue using RT-qPCR and compared to levels in F13a-/- mice. Bars represent 




FXIII-A does not increase F13b transcription. Previous studies7,10 and our in vivo data 
(Figure 4.1), show that FXIII-B levels continue to rise even after all infused FXIII-A is bound to 
endogenous FXIII-B. These findings suggest that FXIII-A also induces de novo FXIII-B 
production. We first hypothesized that FXIII-A increases F13b gene expression. F13b mRNA 
was previously detected in only the mouse liver and kidney4. Recent RiboTag pulldown/RNAseq 
experiments also detected F13b mRNA in mouse liver and kidney (Audrey C. A. Cleuren, 
personal communication). Therefore, to determine the effect of FXIII-A on F13b expression, we 
measured F13b mRNA in both mouse liver and kidney. RT-qPCR revealed no differences in 
liver or kidney F13b transcript levels in F13a+/+, F13a-/-, and rFXIII-A2-treated F13a-/- mice 
(Figure 4.3). These findings indicate that FXIII-A does not increase F13b gene expression.  
 
FXIII-A increases liver RNA-binding proteins. We next hypothesized that FXIII-A 
regulates FXIII-B via a post-transcriptional mechanism. To identify proteins FXIII-A alters in 
the liver, we performed label-free quantitative proteomic profiling of F13a+/+, F13a-/-, and 
rFXIII-A2-treated F13a-/- liver lysates (Figure 4.4A). Analysis of liver proteomes revealed 96 
differentially regulated proteins (P<0.05). Both principal component analysis (Figure 4.4B) and 
hierarchical clustering (Figure 4.4C) clearly separated the three groups of mice. First, we 
analyzed differences between F13a+/+ and F13a-/- livers. Whereas STRING database functional 
gene ontology term analysis revealed no enrichments in the 26 proteins downregulated in 
F13a+/+ mice, the 43 proteins upregulated in F13a+/+ mice contained 13 proteins implicated in 
RNA-binding (RNA-binding proteins, RBPs). KEGG pathway analysis also revealed that 
proteins involved in glycolysis/gluconeogenesis and metabolism were significantly (P=3.25e-05) 
enriched in F13a+/+ mouse livers, suggesting FXIII-A affects liver metabolic pathways. 
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Figure 4.4. FXIII-A increases liver RNA-binding proteins. (A) Schematic of label-free, 
quantitative proteomic profiling of F13a+/+, F13a-/-, and rFXIII-A2-treated F13a-/- liver lysates 
(N=3-4 mice per group). Data was analyzed using MaxQuant and Perseus. (B) Principal 
component analysis separates the three groups of mice, each dot representing one mouse. (C) 
Heat map of significantly altered (ANOVA P<0.05) proteins between mouse groups following 
hierarchical clustering (blue=downregulated, red=upregulated). Venn diagrams show the number 
of downregulated (D) and upregulated (E) proteins in F13a+/+ versus F13a-/- and rFXIII-A2-
treated F13a-/- versus F13a-/- mice. STRING database protein interaction networks for 
downregulated (F) and upregulated (G) proteins in both F13a+/+ and rFXIII-A2-treated F13a-/- 
mice versus F13a-/- mice. In (G), RNA-binding proteins are indicated in red. 
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We next examined proteins specifically altered in both F13a+/+ and rFXIII-A2-treated F13a-/- 
mice relative to F13a-/- mice (Figure 4.4D-E). STRING analysis did not identify any significant 
enrichment in the 6 proteins downregulated in both F13a+/+ and rFXIII-A2-treated F13a-/- mice 
(Figure 4.4F). Conversely, many of the RBPs that were upregulated in F13a+/+ mice relative to 
F13a-/- mice were also upregulated in the rFXIII-A2-treated F13a-/- mice. In total, 11 of the 19 
upregulated proteins (58%) are RBPs (P=5.37e-06) implicated in mRNA processing (P=1.74e-
06, Figure 4.4G). Collectively, these findings suggest FXIII-A specifically regulates the liver 
proteome and may promote liver FXIII-B production via RBP-mediated post-transcriptional 
regulation. 
 
FXIII-A infusion causes kidney ribosome reduction. Given that F13b mRNA is also 
detected in the kidney4, we evaluated mouse kidney lysates for proteomic changes similar to 
those observed in the liver. Label-free quantitative proteomic profiling of F13a+/+, F13a-/-, and 
rFXIII-A2-treated F13a-/- kidney lysates (Figure 4.5) revealed 402 differentially regulated 
proteins, over 4-fold more than in the liver. Similar to the liver proteomics, both principal 
component analysis (Figure 4.5B) and hierarchical clustering (Figure 4.5C) separated the three 
groups of mice. Although overall more differentially regulated proteins were detected in the 
kidney than the liver, fewer proteins were altered in both F13a+/+ and rFXIII-A2-treated F13a-/- 
mice relative to F13a-/- mice (Figure 4.5D-E). In contrast to the liver, STRING analysis did not 
reveal a significant number of interactions among proteins altered in both F13a+/+ and rFXIII-
A2-treated F13a-/- mice relative to F13a-/- mice (Figure 4.5F-G). Interestingly, a large number of 
proteins (98) were downregulated in the rFXIII-A2-treated F13a-/- kidneys relative to both F13a-/- 
and F13a+/+ kidneys (Figure 4.6A). STRING functional analysis showed multiple enrichments,  
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Figure 4.5. FXIII-A and the mouse kidney proteome. (A) Schematic of label-free, quantitative 
proteomic profiling of F13a+/+, F13a-/-, and rFXIII-A2-treated F13a-/- kidney lysates (N=4 mice 
per group). Data was analyzed using MaxQuant and Perseus. (B) Principal component analysis 
separates the three groups of mice, each dot representing one mouse. (C) Heat map of 
significantly altered (ANOVA P<0.05) proteins between mouse groups following hierarchical 
clustering (blue=downregulated, red=upregulated). Venn diagrams show the number of 
downregulated (D) and upregulated (E) proteins in F13a+/+ versus F13a-/- and rFXIII-A2-treated 
F13a-/- versus F13a-/- mice. STRING database protein interaction networks for downregulated 





Figure 4.6. Ribosomal structural proteins are downregulated in rFXIII-A2-infused mouse 
kidneys. (A) Venn diagram showing the number of downregulated proteins in rFXIII-A2-treated 
F13a-/- versus F13a+/+ and F13a-/- mice. (B) STRING database protein interaction network for 




notably of ribosomal structural proteins (P=1.02e-16) and proteins involved in peptide 
metabolism (P=4.95e-18, Figure 4.6B). These markedly divergent trends in F13a+/+ and rFXIII-
A2-treated mice suggest that FXIII-A does not exhibit the same regulatory specificity for the 
kidney as observed in the liver and that the kidney is not the site of FXIII-A-mediated FXIII-B 
production. 
 
FXIII-A increases FXIII-B production in hepatocellular carcinoma cells. To determine 
the cellular mechanism of FXIII-A-mediated FXIII-B induction, we developed an in vitro model 
of FXIII-B production. Tie2+-Cre RiboTag pulldown/RNAseq experiments revealed F13b 
mRNA was enriched in liver parenchymal cells, not endothelium (Audrey C. A. Cleuren, 
personal communication). Therefore, we measured FXIII-B production in hepatocellular 
carcinoma (Huh7) cells. We detected low-level basal FXIII-B production in Huh7 culture 
supernatants and confirmed this finding using siRNA knockdown (Figure 4.7A). IL-6 or LPS 
treatment did not change FXIII-B production (data not shown). Conversely, rFXIII-A2 treatment 
increased Huh7 FXIII-B production nearly 2-fold relative to vehicle (1.98-/+0.86-fold, N=5). 
rFXIII-A2 did not increase Huh7 proliferation (Figure 4.7B). We also observed similar FXIII-B 
production trends in a second hepatocellular carcinoma line (HepG2, data not shown). 
Collectively, these data confirm our proteomics data suggesting a liver-specific effect of FXIII-
A. These data also suggest FXIII-A acts directly on hepatocytes to induce FXIII-B production. 
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Figure 4.7. rFXIII-A2 increases FXIII-B production in Huh7 cells. (A) Huh7 culture 
supernatants from cells grown in the absence or presence of rFXIII-A2 (20 µg/mL) were 
collected 3 days following transfection with the indicated siRNAs (NC=Negative Control, Sham 
did not receive siRNA). Culture supernatant was concentrated 10-fold and FXIII-B visualized 
using Western blot with anti-FXIII-B antibody. Representative of N=5 Huh7 culture 
experiments. (B) Huh7 proliferation following treatment with the indicated concentration of 





The role of FXIII-B in stabilizing FXIII-A is well established4,7,14,18; however, clinical 
observations suggesting FXIII-A regulates FXIII-B7,8 have not been investigated. Our study 
combines mouse models, proteomics, and cell biology to provide insight into this unique 
reciprocal regulatory mechanism. First, our data indicate FXIII-A induces FXIII-B production. 
This finding is important as it exposes unique, inter-tissue crosstalk critical for normal 
hemostasis and identifies in vivo and in vitro model systems for mechanistic studies. Second, our 
proteomics studies show that FXIII-A specifically increases RBPs in the mouse liver, but not in 
the kidney. This exciting finding identifies a tissue-specific effect of FXIII-A. Third, our analysis 
reveals several upregulated RBPs are post-transcriptional regulators. Together with our 
observation that FXIII-A does not alter F13b transcript levels, these findings suggest FXIII-A 
may regulate FXIII-B, and possibly other proteins, via a post-transcriptional regulatory 
mechanism. Further investigation of these findings will extend our understanding of FXIII-A-
mediated liver regulation and the role of RBPs in the liver. 
Our in vivo studies indicate FXIII-A regulates FXIII-B via two mechanisms. First, we found 
that FXIII-A slightly reduces FXIII-B clearance (Figure 4.2). This stabilizing effect is consistent 
with indirect estimates from pharmacokinetic modeling of rFXIII-A2 infusion in monkeys 
(uncomplexed FXIII-B t1/2 ~4 hours)18. This short estimated half-life is surprising given that 
FXIII-B both profoundly stabilizes FXIII-A and circulates bound to fibrinogen9 (fibrinogen t1/2 
~4 days)19. We observed that fibrinogen does not mediate FXIII-B levels (Figure 4.1C), 
suggesting a unique, uncharacterized FXIII-B clearance mechanism. We9 and others20 have 
observed spontaneous precipitation of isolated FXIII-B in certain experiments. Perhaps 
uncomplexed FXIII-B is less soluble than FXIII-A-bound FXIII-B, and this reduced solubility 
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promotes FXIII-B clearance. Alternatively, FXIII-B may possess a clearance-promoting epitope 
that is obscured in FXIII-A2B2. Further study is required to determine how FXIII-B is cleared 
from plasma. 
Second, our data show FXIII-A also induces de novo FXIII-B production. In our model, 
FXIII-A enters a phase of slow decay 6-9 hours post-infusion, indicating all infused FXIII-A 
bound circulating FXIII-B. However, FXIII-B levels rise until 30 hours post-infusion (Figure 
4.1E-F). This trend in FXIII-B levels is consistent with observations in both monkeys10 and 
humans7; FXIII-B continues to rise even in the absence of uncomplexed FXIII-A. These findings 
indicate that the body increases plasma FXIII-B to maintain a pool of excess FXIII-B. Whether 
this response is to protect newly-synthesized FXIII-A or is related to uncharacterized FXIII-B 
functions is unknown. Together with the observation that FXIII-A stabilizes FXIII-B, these data 
reveal a unique pharmacokinetic relationship between FXIII subunits. We are currently 
developing a novel, indirect pharmacokinetic model of this relationship that incorporates both 
FXIII-A-mediated FXIII-B stabilization and induction. 
Our discovery that FXIII-A upregulates liver RBPs begins to uncover the mechanism of 
FXIII-A-mediated FXIII-B induction. Although there are more than 1500 RBPs, the function and 
specificity of these proteins remain largely unknown.21 RBPs identified in our study are 
implicated in a wide array of post-transcriptional processes ranging from splicing22,23 to mRNA 
transport24 and translation25,26, suggesting FXIII-A may modulate post-transcriptional regulation 
of existing F13b RNA in mice. This premise is consistent with our observations that FXIII-A 
does not increase F13b transcription (Figure 4.3) or promote release of FXIII-B protein from 
intracellular stores (data not shown). However, how the identified RBPs may post-
transcriptionally regulate F13b RNA is still unclear. Analysis of the human F13B mRNA 
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transcript with RBPmap, a database of RBP binding motifs27, identifies many RBP binding sites 
in the F13B transcript sequence, including sites for two upregulated liver RBPs (heterogeneous 
nuclear ribonucleoprotein C and TAR DNA-binding protein 43). Both these proteins are 
implicated in translational regulation.25,26 Interestingly, the large number of RBP binding sites on 
F13B mRNA is consistent with RBP-knockdown experiments in HepG2 cells that found dozens 
of RBPs regulate F13B transcript levels (Daniel Dominguez, personal communication). 
However, this study only assessed F13B transcript levels and not F13B translation. Moreover, 
RNA structure, and not sequence alone, is a critical mediator of RBP-RNA interactions.28 Future 
study will validate the FXIII-A-upregulated RBPs and identify which regulate F13B transcripts.  
Beyond regulation of FXIII-B, our findings reveal a newly-recognized role of FXIII-A in 
modulating liver function. Yet, how FXIII-A-mediated RBP changes regulate the liver is unclear. 
RBPs have diverse regulatory functions. Genetic deletion of certain FXIII-A-regulated RBPs is 
embryonic lethal in mice.29-31 Furthermore, dysregulation of RBPs is implicated in human 
disease, including neurodegeneration32, cardiovascular complications33, and cancer34. 
Interestingly, two of the upregulated liver RBPs identified in our study (polyadenylate binding 
protein 1 and U6 snRNA-associated Sm-like protein) are also upregulated in human 
hepatocellular carcinoma.35 We are currently performing parallel RNAseq and ribosome 
profiling of F13a+/+ and F13a-/- liver RNA to determine the transcriptional and translational 
consequences of the differential RBP profiles. Future studies will also examine the signaling 
mechanism connecting FXIII-A and increased liver RBPs. Collectively, these experiments will 
provide insight into how FXIII-A and RBPs contribute to liver function in health and disease. 
FXIII-A is found in both plasma and cellular compartments16, and the relative contributions 
of each to liver function is unknown. Interestingly, both principle component analysis and 
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hierarchical clustering of differentially regulated liver proteins clearly separated the three groups 
of mice (Figure 4.4B-C). As only plasma FXIII-A was reconstituted in the rFXIII-A2-infused 
mice, analysis of differentially-expressed proteins in these mice versus F13a+/+ mice may 
illuminate the relative effects of plasma and cellular FXIII-A. For example, we showed that 
proteins involved in gluconeogenesis/glycolysis and metabolism were upregulated in F13a+/+ 
mice and not rFXIII-A2-treated F13a-/- mice. Whether cellular FXIII-A in the liver drives this 
difference is unclear. 
Although F13b mRNA is detected in the mouse kidney (Figure 4.3 and 4), our data suggest 
this tissue is not the site of FXIII-A-mediated FXIII-B production. Whereas liver proteomics 
revealed significant upregulation of RBPs in both F13a+/+ and rFXIII-A2-treated F13a-/- mice, 
we did not detect similar enrichment in the kidney. Interestingly, a large number of cytoplasmic 
and mitochondrial ribosome structural proteins were downregulated in rFXIII-A2-infused mice 
relative to uninfused (F13a+/+ and F13a-/-) mice (Figure 4.5 and 4.6). Ribosome reduction was 
recently identified as a proteomic biomarker of arsenic-induced cell toxicity36, and mitochondrial 
dysfunction is observed during acute kidney injury37. Although our rFXIII-A2 dose (4 mg/kg) 
was ~10-fold higher than a human therapeutic dose, this dosage was well-tolerated in previous 
mouse studies.14 Our dosage is also well below the 22.5 mg/kg required for overt toxicity in 
monkeys.10 At this high dose, excess infused rFXIII-A2 becomes activated, crosslinks circulating 
fibrinogen, and causes systemic coagulopathy.10 This observation is consistent with experiments 
where we infused F13a-/- mice with pre-activated rFXIII-A2 (data not shown). However, at the 4 
mg/kg dose of unactivated rFXIII-A2 we did not detect any intravascular fibrinogen crosslinking 
(data not shown). Indications of kidney cell stress in rFXIII-A2-infused mice may signify that 
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rFXIII-A2 accumulates in the kidneys, but further investigation is required to support this 
premise. 
Our study has potential limitations. First, we used human, not mouse, rFXIII-A2 in this study. 
However, we (Figures 4.1) and others14 showed mouse FXIII-B enhances circulation of human 
rFXIII-A2, indicating rFXIII-A2 binds mouse FXIII-B. Moreover, we observed similar rFXIII-
A2-mediated FXIII-B induction in both our murine and human model systems. Second, F13a-/- 
mice are only ~90% FXIII-B-deficient. Therefore, we did not perform our FXIII-B subunit 
clearance studies (Figure 4.2) in a completely FXIII-B-free system. However, we corrected for 
background FXIII-B when determining the FXIII-B present at each time-point. Lastly, the 
proteomic changes in both liver and kidney tissue require further validation. However, the 
strength of liver RBP enrichment, and the use of both genetic (F13a+/+) and pharmacologic 
(rFXIII-A2-infused F13a-/-) models of FXIII-A sufficiency strongly suggest FXIII-A upregulates 
these proteins. Planned ribosome profiling and Western blotting experiments will further validate 
these proteins and identify additional proteins of interest. 
In summary, our data expose the unique, inter-tissue, reciprocal regulation of FXIII-A and -B 
subunits. Although other examples of reciprocal regulation exist in biology, these are largely at 
the intracellular11,38 or whole-cell12,39 levels. To our knowledge, we are the first to describe an 
inter-tissue, systemic, regulatory relationship between protein subunits. FXIII-B stabilizes FXIII-
A, and FXIII-A promotes FXIII-B stability and production. Our observation that FXIII-A 
upregulates liver RBPs provides insight into potential post-transcriptional regulation of FXIII-B 
and uncovers a newly-recognized liver-regulatory function of FXIII-A. Continued study will 
refine the mechanism of FXIII-A-mediated FXIII-B production and expand our understanding of 




1. Wolpl A, Lattke H, Board PG, Arnold R, Schmeiser T, Kubanek B, Robin-Winn M, 
Pichelmayr R, Goldmann SF. Coagulation factor XIII A and B subunits in bone marrow 
and liver transplantation. Transplantation. 1987;43(1):151-153. 
	  
2. Beckers CML, Simpson KR, Griffin KJ, Brown JM, Cheah LT, Smith KA, Vacher J, 
Cordell PA, Kearney MT, Grant PJ, Pease RJ. Cre/lox Studies Identify Resident 
Macrophages as the Major Source of Circulating Coagulation Factor XIII-A. Arterioscler 
Thromb Vasc Biol. 2017;37(8):1494-1502. 
 
3. Nagy JA, Henriksson P, McDonagh J. Biosynthesis of factor XIII B subunit by human 
hepatoma cell lines. Blood. 1986;68(6):1272-1279. 
 
4. Souri M, Koseki-Kuno S, Takeda N, Degen JL, Ichinose A. Administration of factor XIII 
B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-
out mice. Int J Hematol. 2008;87(1):60-68. 
 
5. Katona E, Penzes K, Csapo A, Fazakas F, Udvardy ML, Bagoly Z, Orosz ZZ, Muszbek 
L. Interaction of factor XIII subunits. Blood. 2014;123(11):1757-1763. 
 
6. Fear JD, Miloszewski KJ, Losowsky MS. The half life of factor XIII in the management 
of inherited deficiency. Thromb Haemost. 1983;49(2):102-105. 
 
7. Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, 
Pederson SM, Ishak LM, Nugent DJ. Safety and pharmacokinetics of recombinant factor 
XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 
2006;108(1):57-62. 
 
8. Yorifuji H, Anderson K, Lynch GW, Van de Water L, McDonagh J. B protein of factor 
XIII: differentiation between free B and complexed B. Blood. 1988;72(5):1645-1650. 
 
9. Byrnes JR, Wilson C, Boutelle AM, Brandner CB, Flick MJ, Philippou H, Wolberg AS. 
The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen 
residues gamma390-396 and the FXIII-B subunits. Blood. 2016;128(15):1969-1978. 
 
10. Ponce RA, Visich JE, Heffernan JK, Lewis KB, Pederson S, Lebel E, Andrews-Jones L, 
Elliott G, Palmer TE, Rogge MC. Preclinical safety and pharmacokinetics of recombinant 
human factor XIII. Toxicol Pathol. 2005;33(4):495-506. 
 
11. Ferrell JE, Jr. Feedback loops and reciprocal regulation: recurring motifs in the systems 
biology of the cell cycle. Curr Opin Cell Biol. 2013;25(6):676-686. 
 
12. Shi FD, Van Kaer L. Reciprocal regulation between natural killer cells and autoreactive T 
cells. Nat Rev Immunol. 2006;6(10):751-760. 
 106 
13. Souri M, Koseki-Kuno S, Takeda N, Yamakawa M, Takeishi Y, Degen JL, Ichinose A. 
Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII. 
Thromb Haemost. 2008;99(2):401-408. 
 
14. Andersson C, Kvist PH, McElhinney K, Baylis R, Gram LK, Pelzer H, Lauritzen B, 
Holm TL, Hogan S, Wu D, Turpin B, Miller W, Palumbo JS. Factor XIII 
Transglutaminase Supports the Resolution of Mucosal Damage in Experimental Colitis. 
PLoS One. 2015;10(6):e0128113. 
 
15. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, 
Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. 
STRING v10: protein-protein interaction networks, integrated over the tree of life. 
Nucleic Acids Res. 2015;43(Database issue):D447-452. 
 
16. Kattula S, Byrnes JR, Martin SM, Holle LA, Cooley BC, Flick MJ, Wolberg AS. Factor 
XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous 
thrombus size in mice. Blood Adv. 2018;2(1):25-35. 
 
17. Aleman MM, Byrnes JR, Wang JG, Tran R, Lam WA, Di Paola J, Mackman N, Degen 
JL, Flick MJ, Wolberg AS. Factor XIII activity mediates red blood cell retention in 
venous thrombi. J Clin Invest. 2014;124(8):3590-3600. 
 
18. Dodds MG, Visich JE, Vicini P. Population pharmacokinetics of recombinant factor XIII 
in cynomolgus monkeys. AAPS J. 2005;7(3):E693-703. 
 
19. Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM. 
2003;96(10):711-729. 
 
20. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to 
fibrinogen molecules containing γʹ chains. Biochemistry. 1996;35(32):10448-10453. 
21. Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev 
Genet. 2014;15(12):829-845. 
 
22. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with 
splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin 
Invest. 1993;92(5):2419-2426. 
 
23. Hui J, Stangl K, Lane WS, Bindereif A. HnRNP L stimulates splicing of the eNOS gene 
by binding to variable-length CA repeats. Nat Struct Biol. 2003;10(1):33-37. 
 
24. Yamazaki T, Fujiwara N, Yukinaga H, Ebisuya M, Shiki T, Kurihara T, Kioka N, Kambe 
T, Nagao M, Nishida E, Masuda S. The closely related RNA helicases, UAP56 and 
URH49, preferentially form distinct mRNA export machineries and coordinately regulate 
mitotic progression. Mol Biol Cell. 2010;21(16):2953-2965. 
 107 
25. Kim JH, Paek KY, Choi K, Kim TD, Hahm B, Kim KT, Jang SK. Heterogeneous nuclear 
ribonucleoprotein C modulates translation of c-myc mRNA in a cell cycle phase-
dependent manner. Mol Cell Biol. 2003;23(2):708-720. 
 
26. Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, Dewey CM, Roth FP, 
Herz J, Peng J, Moore MJ, Yu G. Identification of neuronal RNA targets of TDP-43-
containing ribonucleoprotein complexes. J Biol Chem. 2011;286(2):1204-1215. 
 
27. Paz I, Kosti I, Ares M, Jr., Cline M, Mandel-Gutfreund Y. RBPmap: a web server for 
mapping binding sites of RNA-binding proteins. Nucleic Acids Res. 2014;42(Web Server 
issue):W361-367. 
 
28. Li X, Kazan H, Lipshitz HD, Morris QD. Finding the target sites of RNA-binding 
proteins. Wiley Interdiscip Rev RNA. 2014;5(1):111-130. 
 
29. Williamson DJ, Banik-Maiti S, DeGregori J, Ruley HE. hnRNP C is required for 
postimplantation mouse development but is dispensable for cell viability. Mol Cell Biol. 
2000;20(11):4094-4105. 
 
30. Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, 3rd, Herz J, Yu G. TDP-43 is a 
developmentally regulated protein essential for early embryonic development. J Biol 
Chem. 2010;285(9):6826-6834. 
 
31. Gaudreau MC, Heyd F, Bastien R, Wilhelm B, Moroy T. Alternative splicing controlled 
by heterogeneous nuclear ribonucleoprotein L regulates development, proliferation, and 
migration of thymic pre-T cells. J Immunol. 2012;188(11):5377-5388. 
 
32. Nussbacher JK, Batra R, Lagier-Tourenne C, Yeo GW. RNA-binding proteins in 
neurodegeneration: Seq and you shall receive. Trends Neurosci. 2015;38(4):226-236. 
 
33. de Bruin RG, Rabelink TJ, van Zonneveld AJ, van der Veer EP. Emerging roles for 
RNA-binding proteins as effectors and regulators of cardiovascular disease. Eur Heart J. 
2017;38(18):1380-1388. 
 
34. Hong S. RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention 
and Treatment. J Cancer Prev. 2017;22(4):203-210. 
 
35. Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, 
Hughes TR, Wang XW. Oncogenic Activation of the RNA Binding Protein NELFE and 
MYC Signaling in Hepatocellular Carcinoma. Cancer Cell. 2017;32(1):101-114 e108. 
 
36. Guerra-Moreno A, Isasa M, Bhanu MK, Waterman DP, Eapen VV, Gygi SP, Hanna J. 
Proteomic Analysis Identifies Ribosome Reduction as an Effective Proteotoxic Stress 
Response. J Biol Chem. 2015;290(50):29695-29706. 
 
 108 
37. Ralto KM, Parikh SM. Mitochondria in Acute Kidney Injury. Semin Nephrol. 
2016;36(1):8-16. 
 
38. Li F, Abuarab N, Sivaprasadarao A. Reciprocal regulation of actin cytoskeleton 
remodelling and cell migration by Ca2+ and Zn2+: role of TRPM2 channels. J Cell Sci. 
2016;129(10):2016-2029. 
 
39. Kalim KW, Yang JQ, Li Y, Meng Y, Zheng Y, Guo F. Reciprocal Regulation of 
Glycolysis-Driven Th17 Pathogenicity and Regulatory T Cell Stability by Cdc42. J 




CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
	  
	  
5.1 Summary and future directions 
Current anticoagulant therapies target coagulation enzymes upstream of fibrin formation and 
are associated with a risk of bleeding.1 Basic studies examining the fundamental mechanisms 
underlying coagulation are therefore required to identify new therapeutic strategies that will 
reduce thrombosis yet preserve physiologic hemostasis. The studies presented in this dissertation 
investigate the interactions between factor XIII (FXIII), fibrin(ogen), and red blood cells (RBCs) 
at the terminal end of the coagulation cascade. Our findings greatly expand our understanding of 
how this axis functions in coagulation and the regulation of its components. Importantly, these 
studies emphasize the importance of basic biological studies to support translational research 
efforts. 
In Chapter 2, we determined the mechanism of FXIIIa-mediated RBC retention in clots.2 
This study was an important follow-up to our discovery that FXIIIa promotes RBC retention in 
clots.3 We used several assays to first test the hypothesis that FXIIIa directly crosslinked RBCs 
to the fibrin network. We did not find any evidence of direct RBC-crosslinking to clots. Instead, 
we found that FXIIIa promotes RBC retention through its fibrin crosslinking function. 
Interestingly, our experiments using recombinant fibrinogen variants and selective FXIIIa 
inhibitor dosing revealed that crosslinking of the fibrin α-chains, but not γ-chains, was crucial for 
normal RBC retention in clots. This finding suggests that α-chain-dependent stiffening4-7 of the 
fibrin network is necessary to trap RBCs within a contracting clot. If the fibrin is insufficiently 
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crosslinked, the RBCs are able to escape the clot, resulting in reduced RBC retention and 
reduced clot size. 
The implications of this study are multifaceted. First, we identified a pathophysiologic 
function of α-chain crosslinking in mediating RBC retention. The role of α-chain crosslinking in 
modifying clot biophysical properties has been a recent focus of investigation5-7, and our findings 
provide an important connection between those studies and the biological function of this 
crosslinking in vivo. Second, these findings reveal the mechanism of FXIIIa-mediated RBC 
retention in clots, an important advancement in the development of therapies targeting FXIIIa to 
reduce venous thrombosis.3 Interestingly, our observation that γ-γ dimer and α-chain crosslinking 
are inhibited at different levels of FXIIIa inhibitor suggest that complete inhibition of FXIIIa 
may not be necessary to reduce venous thrombus size. The dose of FXIIIa inhibitor could be 
titrated to inhibit primarily α-chain crosslinking and leave γ-γ dimer formation intact. Although 
this titration would be clinically difficult and the contribution of γ-γ dimer formation to clot 
mechanical strength is limited5-7, preservation of some FXIIIa activity while still reducing 
thrombus size may reduce the risk of treatment-associated bleeding. 
In Chapter 3, we characterized the binding interaction between zymogen FXIII-A2B2 and 
fibrinogen.8 This study extended our prior observation that this interaction is a crucial mediator 
of RBC retention in murine clots3 into a human system. Our use of several recombinant 
fibrinogen variants and multiple assays examining FXIII-fibrinogen binding (e.g. glycine 
precipitation, surface plasmon resonance, FXIII activation/fibrin crosslinking) not only revealed 
that the same fibrinogen residues (γ390-396) implicated in mouse FXIII-fibrinogen binding 
interactions3 mediate this interaction in humans, but also clarified a controversial topic in the 
literature. The FXIII-A2B2 binding site on human fibrinogen has been unclear since the 
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interaction was first discovered over 30 years ago.9 Prior studies implicated the alternatively 
spliced γʹ-chain10,11 and residues in the αC region as FXIII-A2B2 binding sites.12 Our study used 
recombinant fibrinogen variants to investigate these prior observations and clarify the fibrinogen 
residues involved in this interaction. We showed that the γʹ-chain is not necessary for FXIII-
A2B2 binding and exposed fibrinogen γ-chain residues 390-396 as crucial mediators of this 
interaction. Importantly, we also demonstrated that the FXIII-B subunits bind fibrinogen and that 
the pool of excess FXIII-B in plasma circulates bound to fibrinogen. 
These findings are important for several reasons. First, we clarified a controversial literature 
and were able to develop a model of FXIII-fibrinogen binding and activation that incorporates 
findings from decades of studies. Second, we identified the importance of fibrinogen γ-chain 
residues 390-396 in binding FXIII-A2B2. As we previously identified this interaction as a key 
regulator of venous thrombus size3, our findings expose another avenue to target FXIII to reduce 
venous thrombosis. Instead of inhibiting FXIIIa activity, a therapy could instead target the FXIII-
fibrinogen interaction. This would delay FXIII activation and reduce thrombus size, while still 
maintaining a patient’s ability to eventually crosslink a clot. Given that mice with disrupted 
FXIII-fibrinogen binding exhibit reduced thrombus size in venous thrombosis models3, yet do 
not have a bleeding phenotype in hemostasis models, suggests this may be a viable anti-
thrombotic strategy. However, therapeutically targeting protein-protein interactions is difficult13, 
and further study is required to identify the precise FXIII-B and fibrinogen involved in binding. 
Chemical crosslinking with mass spectrometry, hydrogen-deuterium exchange, site-directed 
mutagenesis, and molecular modeling experiments could further clarify the respective FXIII and 
fibrinogen binding regions and implicate specific residues involved in binding. Such studies 
would inform efforts to therapeutically target FXIII, and therefore warrant future investigation. 
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In Chapter 4, we investigated clinical observations that suggest FXIII-A regulates FXIII-
B.14,15 Using a diverse approach incorporating mouse models, proteomics, and cell culture, we 
found that FXIII-A both stabilizes FXIII-B in circulation and induces de novo liver FXIII-B 
production. FXIII-A did not change liver F13b transcript levels, but increased liver RNA-binding 
proteins (RBPs). This finding suggests FXIII-A may signal the liver to alter post-transcriptional 
regulation of F13b transcripts. We did not observe a similar RBP increase in the kidney, 
suggesting the effect of FXIII-A is liver-specific. Consistent with this premise, cultured human 
hepatocellular carcinoma cells produced FXIII-B and exhibited increased FXIII-B production 
when treated with FXIII-A. 
This study is exciting as it identifies a unique, inter-tissue reciprocal regulatory relationship 
between two protein subunits. These findings also suggest a liver-regulatory role of FXIII-A. 
Still, many mechanistic questions remain. Most importantly, the signaling pathway connecting 
FXIII-A with increased liver RBP and plasma FXIII-B levels is unclear. Although Tie2+-Cre 
RiboTag pulldown/RNAseq experiments showed F13b mRNA was enriched in liver 
parenchymal cells, it is possible that FXIII-A interacts with the liver endothelium, which in turn 
signals the parenchyma. However, our in vitro data suggest FXIII-A signals directly to 
hepatocytes. The hepatocyte receptor for FXIII-A remains unknown, but preliminary in vitro 
experiments suggest FXIII-A crosslinking activity is not required to induce FXIII-B. Another 
possibility is that FXIII-A does not directly signal the liver, and instead the liver senses the 
decrease in uncomplexed plasma FXIII-B following rFXIII-A2 treatment. Ongoing experiments 
will blend our proteomics data with transcriptomics, ribosome profiling16, 3D hepatocyte 
spheroid culture17, and in vitro and in vivo siRNA knockdowns to further define the FXIII-A 
signaling mechanism. Furthermore, data from the Tie2+-Cre RiboTag pulldown/RNAseq 
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experiments will also help identify any endothelial- versus hepatocyte-specific effectors. 
Collectively, these studies will define the liver-specific effect of FXIII-A and provide insight into 
how FXIII-A and RBPs affect liver function. 
In summary, this dissertation clarifies the interactions between FXIII, fibrin(ogen), and RBCs 
in coagulation. The studies presented here inform continued efforts to therapeutically target 
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